HUMAN BRAIN, MUSCLE AND ADIPOSE TISSUES MATHEMATICAL MODELING FOR NORMAL AND DISEASED STATE STUDIES by Park, Hyun
HUMAN BRAIN, MUSCLE AND ADIPOSE TISSUES  
MATHEMATICAL MODELING FOR NORMAL AND DISEASED STATE STUDIES 
by 
Hyun Park 
A thesis submitted to Johns Hopkins University in conformity with the requirements for the 









Recent advances in biology, biochemistry, and medicine allow us to study – both qualitatively and 
quantitatively - the human body’s response to a variety of perturbations. So, for example, we know 
quantitatively what will happen to insulin levels when a person is eats a meal; in many cases, we 
also know qualitatively the genes and signaling molecules will be stimulated or suppressed. These 
qualitative and quantitative data can be curated for statistical meta-studies and/or building 
mathematical models. Such mathematical models are made based on Transport Phenomena, 
Thermodynamics, Kinetics and PKPD (Pharmacokinetics and Pharmacodynamics) principles. 
This research is concerned with building mathematical models at the organ level (e.g. liver and 
pancreas), combining such organ models into a whole-body model such that we can better 
understand metabolism (or both normal and diseased people) under different conditions such as 
homeostasis, postprandium, exercise and so on. In particular, we have made a detailed, yet not too 
complicated, whole-body model to the body’s response to glucose in normal people and in those 
with Type II Diabetes (T2D). Our results are presented in two parts. The other part is written by 
Yifei Li. In my M.S. Thesis, myocyte, adipose and brain organ models are explained using the 
mathematical tools such as Ordinary Differential Equations (ODEs), Flux Balance Analysis (FBA), 
optimization and sensitivity analysis. These models will show concentration and flux change of 
metabolites over time, parameter sensitivity and so on. Secondly, the current research on T2D will 
be explained and we will present our hypotheses on the causes of T2D. Ultimately, the goal is to 
understand and model the body as a complex system with respect of components and interactions. 
With this we hope to understand the essential qualitative and quantitative features of T2D with the 
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1. THE INTRODUCTION 
This Masters Essay presents a comprehensive physiologic model of glucose uptake, metabolism, 
and storage in the human body.  The purpose in building this model are: 
(1) To organize the breadth of information on this topic into a coherent picture of glucose 
utilization; and 
(2) To understand and model the complex behavior of glucose in the body with respect to all   
the key components and interactions involved in glucose utilization. 
The goals of this research are to understand the essential qualitative features of glucose uptake, 
metabolism and storage, to correct errors in the conventional views of glucose behavior, as well 
as to develop new strategies for treating Type 2 Diabetes.  The model developed covers the 
essential mechanisms that occur in the liver, brain, muscle, and adipose tissue.  In addition to 
correcting errors in those models, it is hoped that the model presented here will expand on previous 
work by including physiological factors which, to best of knowledge, have not appeared in prior 
models of this system.  In particular, in the model presented here differs in three ways from all 
prior models.  They are: (1) Energy intake and expenditure are decoupled;  fat intake leads to the 
production of ATP, but increased fat intake does not necessarily produce more ATP based on mass 
balance; instead, the amount of ATP a person consumes stays the same unless the person exercises.  
(2) Intracellular dissolvable and non-dissolvable metabolites (triglyceride and glycogen) are 
differentiated. Their dynamic behaviors are different; hence, it is necessary to devise separate 
equations instead of using the same equation. (3) Key enzyme interactions are determined using 
sensitivity analysis. Although a human body can convert one chemical into another as a chemical 
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reactor does, the actual process is much more complicated.  One cannot build an in vivo model if 









2. PREVIOUS EFFORTS IN BUILDING MODELS OF GLUCOSE 
UTILIZATION 
2.1 Systems biology model 
Systems biology is a biology-based interdisciplinary field that focuses on complex interactions 
within biological systems (Palsson, Bernhard 2015). It is a holistic approach to deciphering the 
complexity of biological systems.  Systems biology uses mathematical models to help understand 
the dynamic process and reaction networks of living systems (Noguchi, R 2013). 
E. coli is an organism that has been thoroughly studied. The reason most comprehensive modeling 
simulations have been done on E coli is that it is the best-characterized organism in the world. 
Feist (2008) and Palsson (2015) both did thorough information gathering on E coli systems biology 
modeling.    
There is a process when it comes to building models for systems biology models like those for E. 
coli.  It is based primarily on flux balance analysis, which includes: a) curating metabolic reactions, 
b) formulating the stoichiometric matrix (S matrix), c) applying mass balance constraints, d) 
defining the objective function(s), and e) optimizing the objective function using linear 
programming. 
2.2 Human models 
Over the past five decades, there has been considerable effort modeling glucose, fat and their 
regulatory hormones and these models have been used widely to help understand diabetes and 
related complications.  
Combined circulatory and organ models of glucose and insulin interaction by Tiran (1980) have 
been developed based on a prior model of insulin and glucose by Tiran (1975). However, these 
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models do not show the detailed kinetics of how metabolites react and convert within an organ. In 
other words, they are not systems biology models. Sorensen (1985) developed an organ model for 
glucose metabolism by using features from different models, serving as a foundation for other 
models.  Ajmera (2013) did a study of mathematical models of diabetes listing hundreds of models.   
2.3 Human metabolite system biology model 
The accomplishment of applying systems biology to bacteria like E. coli made it possible for 
researchers to develop detailed kinetics systems biology models for specific organs, and the liver 
has received the most attention. The liver, as the primary metabolic factory of the human body, is 
very important for storing and converting energy and for keeping the human body healthy.  
Different hepatic models serve different functions and predict different trends in the role of hepatic 
glycogen regulation. Xu (2011) suggested a physiological model about glycogen metabolism in 
maintaining blood glucose homeostasis. Recently, Koenig (2012) presented a novel kinetic model 
of human hepatic glucose metabolism. This model includes glucose metabolic pathways in human 
liver along with the hormonal control of these pathways. 
2.4 Discussion and what can be improved 
There has been a significant increase in human systems biology modeling, particularly with respect 
to the increasing complexity of these models.  However, there is still a huge gap between existing 
knowledge of physiology and the features of these mathematical models and there are deficiencies 
in all these models that can be improved. In particular, none of the existing models decouple energy 
(food) intake and energy consumption, many have errors in their physiology and enzyme kinetics, 




3. THE SCOPE OF THIS RESEARCH 
The model presented here describes the relationships between glucose, fatty acid, amino acids, 
ketone bodies, intracellular metabolites such as G6P, F6P, glycogen, lactate, acetyl CoA and 
hormones such as insulin, glucagon and so on. To be more specific, the present model attempts to 
describe what happens to a normal human when the subject is fed, fasts, starves, is administered 
nutrients and exercises.  The model also attempts to simulate how a patient with Type 2 Diabetes 
differs from someone without diabetes with the hope of elucidating the potential causes of  T2D.  
To do this the model presented here must have a highly detailed whole-body model consisting of 
detailed organ/tissue/cell compartment models of a normal human with detailed systemic 
circulation, intracellular metabolism and signaling molecules.. Depending on what the focus is, 
some of the details can be lumped or disregarded. In most cases, signal molecules such as AS160, 
Akt, PI3 etc are omitted and genes such as HIF may not be considered.  
A human whole-body compartment model consists of brain, heart, adipose tissue, muscle, liver 
and peripheral (rest of the organs/tissues/cells) organs/tissues/cells, each having its own 
metabolism and all of which are connected by arteries and veins. Also, under different conditions 
(mainly postprandial, fasting, starvation, administration of nutrients and exercises), simulating 
what happens to concentrations and reaction fluxes of macronutrients and metabolites inside the 
system and organs/tissues/cells is tried.  
The primary focus of model presented here effort is to make a model of human physiology that is 
more realistic than previous models by decoupling energy intake and expenditure.  Why this is 
important and distinct from previous models is because certain energy storage metabolites (energy 
intake) and energy expenditure (Basal Metabolic Rate-BMR- or exercise) are decoupled. Think of 
a car filled with gasoline (energy input) and engine’s power (energy expenditure). In many 
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previous publications, the energy expenditure is dependent on the concentration of energy sources 
in the body; this would be the equivalent of a car’s velocity being dependent on how full the gas 
tank is rather than on the pressure on the gas pedal. . However, physiologically (ie because of the 
decoupling of energy intake and  energy expenditure) this is no more true in the human body than 
it is in an automobile. There are many mechanisms such as allosteric inhibition of enzymes or 
protein binding that stimulate or inhibit the metabolism of a species. While it may be true that 
storage of glycogen or TAG would accumulate as one consumes (energy intake) nutrients, it is 
wrong to say that TAG is used as an energy source because there is much TAG storage. In other 
words, just because one is obese, the obese person would not consume TAG at a higher rate.  
To deal with this problem, in the model presented her, energy expenditure is decoupled from 
energy consumption. That is, to set TAG and glycogen energy expenditure to be independent of 
their concentration. Mathematically speaking, the energy expenditure of both species will be 
determined by basal metabolic rate and additional energy expenditure (i.e. exercise). The 
thermogenesis, digestive and miscellaneous energy expenditure are not considered here. Prior to 
this energy decoupling, stiffness was a major issue. That is, when ATP concentration, glycogen 
and TAG concentration were at extreme values, the model predicted that some of the metabolite 
concentrations became negative, reaction fluxes returned physiologically implausible values and 
optimized Km (Michaelis-Menten constant) and Vmax (maximum reaction rate constant) often 
returned unrealistic values.  
When it comes to the physiology of energy decoupling, glycogen and TAG undergo reactions. 
Rather than being driven by glucose concentration, glycogen accumulates because of two major 
factors: first, the number of proteins called ‘glycogenin’ and second, the kinetics of glycogen 
accumulation (by insulin signaling, glucose and G6P) and degradation (by insulin signaling, 
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glucose and G6P as well). Previously, there has been considerable research describing glycogen 
metabolism with the latter reason only (kinetics).  This may have been due to improper 
understanding of glycogen metabolism or knowing simplification of the equations. This model 
presented here simplifies glycogen metabolism but with a better understanding of this issue. The 
detailed explanation for glycogen metabolism is presented below.  
Glycogen molecules have central proteins called glycogenin which exist in certain amount (may 
be due to thermodynamic equilibrium) and this is the reason why there are multiple glycogens 
detected in liver and muscle cells.  
As for TAG, there are proteins called ‘perilipins’ which are on the surface of lipid droplets - 
primarily in adipose tissue cytoplasm. Lipid droplets are clusters of TAG. Once TAGs are 
absorbed into the white adipose tissues (WAT), they cluster together forming a large lipid droplet 
organelle which pushes the rest of the organelles such as endoplasmic reticulum, nucleus, 
ribosomes and so on to the side. Hence, WAT cells grow in size (hypertrophy) rather than growing 
in number (hyperplasia) as lipid droplets collect more TAGs and vice versa. The lipid droplets, 
however, are not under pressure to go through TAG releasing metabolism just because of its 
concentration. The perilipins hinder lipid droplets from degrading at high concentration. Perilipins 
undergo conformational change to release TAG from lipid droplets, only upon exercise, nutritional 






4. PHYSIOLOGICAL RESEARCH FOR WHOLE-BODY MODEL 
Knowledge of human physiology is not yet developed to the point that one could create a model 
to treat all human physiology and its variation from organ to organ over the whole range of 
physiologic conditions.  Therefore, innumerable assumptions and simplifications necessarily must 
be made. Depending on how detailed or broad one would like to make a whole-body, multi-
compartment model, there are innumerable different possibilities of what the end model would 
look like. For example, there have been some previous attempts at making an endoplasmic 
reticulum (ER) subcompartment and a mitochondrial subcompartment within intracellular 
cytoplasm compartment (or organ/tissue compartment).  The reason for having a mitrochondrial 
subcompartment is that there are several metabolites whose concentrations in cytoplasm and 
mitochondrial matrix are quite different. For the ER, there is a concentration difference of calcium 
ions between the ER and cytoplasm due to calcium sequestration and release by the ER.  
On the other hand, apart from detailing the ‘compartments’, one also may consider the ‘level’ of 
variables. Components which are involved in metabolic network categorized. There are four 
categories one could think of: macronutrients, intracellular metabolites, signal molecules and 
transcription-level agents.  
Macronutrients are, in simple definition, chemicals which can be detected in the system (i.e. blood 
circulation) as a result of administration into the body for energy use or secretion from the 
organs/tissues/cells. Examples include derivatives of carbohydrates, fats and proteins such as 
glucose, fructose, fatty acids, triacylglycerides, amino acids, pyruvate, lactate, glycerol, etc.  
Metabolites, in simple definition, are chemicals which can be only detected in the cytoplasm which 
normally do not exit the organs/tissues/cells. They mostly appear inside the organs/tissues/cells 
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due to the organs/tissues/cells’ specific metabolism. For example, glycogen is present primarily in 
liver and muscle.  Though it can also appear in adipose tissues as well, glycogen is not present in 
blood or plasma. Glucose-6-phosphate is another example of metabolite produced via glycolysis 
or gluconeogenesis but never leaves the cell. One should bear in mind that such intracellular 
metabolism is driven by (mostly protein) enzymes. The enzyme effect is indirectly expressed as 
Vmax and directly as Km.  
Signaling molecules are non-metabolite nor non-enzyme molecules which are involved in 
transduction of signals to make cellular metabolism possible. Some examples are IRS, Akt, AS160 
etc. IRS is an abbreviation for Insulin Receptor Substrate and is a protein which binds to the β 
(intracellular) portion of IR (Insulin Receptor). The β IR undergoes conformation change upon 
insulin binding to the α IR, then IRS binds to β IR. IRS binding to β IR will trigger and propagate 
numerous downstream reactions including PI3K reaction, phosphorylation, AS160 reaction etc. 
Akt is one of the downstream reaction protein involved in transduction and stimulation of other 
signal molecules. AS160 perhaps is responsible for and involved in GLUT4 translocation onto the 
surface of the cellular membrane (of muscle, usually). There will be more detailed explanations in 
later section in this chapter. 
Lastly, transcription-level agents are chemicals involved in genetic level. They control long and 
short term changes of organs/tissues/cells and produce enzymes, signal molecules etc. DNA, 
mRNA and transcription factors are such examples. 
In this model, for simplicity without losing much detailed complexity, macronutrients, 




4.1 Blood macronutrient concentration 
In this model, the following macronutrients are going to be considered. Glucose, Free Fatty 
Acids (palmitate is used to represent the wide variety of FFA), AA (alanine, gluconeogenic 
amino acid), KB (representing general group of ketone bodies, partially oxidized FFA and can 
only be used in cells containing mitochondria: i.e. erythrocyte cannot use KB such as β-
hydroxybutyrate and acetoacetate), glycerol (stoichiometry with fatty acids is important), TAG, 
lactate and pyruvate. Detailed metabolism of these enumerated metabolites will be explained for 
different organs/tissues/cells in the later part of this chapter.  
Nutrients 
Days of Fasting 
(0) 1 2 3 4 5 6 
Concentration                
Glucose (mM) 3.67 4.67 4.05 3.78 3.61 3.67 3.44 
Free Fatty Acids 
(mM) 0.53 0.42 0.82 1.04 1.15 1.27 1.18 
Ketone Bodies (mM) 0.00 0.03 0.55 2.15 2.89 3.64 3.98 
Glycerol (uM) 0.00 62.00 85.00 95.00 91.00 100.00 76.00 
Insulin (pM) 458.33 583.33 506.94 472.22 451.39 458.33 430.55 




4.2 Organ/Tissue/Cellular metabolites 
For metabolites, the research considered the followings. G6P (glucose-6-phosphate), glycogen, 
F6P (fructose-6-phosphate), G3P (glycerol-3-phosphate), OAA (oxaloacetate), AcCoA (acetyl 
coA), NADH, NAD+ (Nicotinamide Adenine Dinucleotide), FADH2, FAD+ (Flavin adenine 
dinucleotide), GTP (Guanine Triphosphate) and GDP.  
G6P is the very first metabolite in this model under glycolysis. Under gluconeogenesis (in liver 
and kidney only), G6P will convert to glucose. Glycogen is a polymer metabolite which stores 
glucose monomers. F6P is a metabolite converted from G6P and both G6P and F6p are in 
thermodynamic equilibrium by a single enzyme responsible for the reversible reaction. G3P is a 
metabolite which can be produced from F6P via multiple reactions, which are lumped in this model. 
In this case, multiple biochemical reactions are lumped into one simplified hypothetical reaction 
represented by ‘phenomenological’ Vmax and Km, rather than experimental values. G3P can also 
be produced from glycerol and be used to produced TAG with fatty acids (stoichiometry, 
G3P:FFA=1:3). Pyruvate is a metabolite produced from G3P via multiple reactions and in this 
model, such reactions are lumped into one reaction. Pyruvate can also be produced from lactate 
and vice versa due to an enzyme responsible for such reversible reaction. Pyruvate is a versatile 
metabolite because it can produce many important metabolites which can be used for TCA cycle, 
which is necessary for generating ATP under aerobic condition through electron transfer and 
proton gradient. Two pyruvate-produced metabolites which are thought to be important in this 
model are OAA and AcCoA. OAA is known as a metabolite which is used as an intermediate 
reactant alongside AcCoA to activate TCA cycle while OAA also can generate G3P. AcCoA is 
responsible for generating multiple ATPs in mitochondria due to its biochemical reaction where it 
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can break down up to 8 times. If for any reasons either OAA or AcCoA depletes, TCA cycle will 
be affected. KB can also be generated from AcCoA and vice versa in some organs/tissues/cells.   
One should keep in mind that some of the intracellular cytoplasmic metabolite also can exist in 
some of the organelles such as mitochondria, a subcompartment. In that case, the concentration of 
the coexisting metabolites may have different concentration in both places or it may be very hard 
to measure the subcompartmental concentration. In such cases, one can choose to disregard 
subcompartmental concentration or assume concentration based on educated guess. In this model, 
subcompartmental concentration is disregarded for simplicity and because it does not affect this 
model much because of the scale of this model. Likewise, due to less importance, pancreatic ER 
subcompartment where it introduces interesting Hodgkin Huxley-like calcium based electro-
oscillation is omitted. It is important to mention that some of the organ specific models (Hodgkin 
Huxley being one of them), can be simplified so that oscillatory behaviors in this case, can be ruled 
out in the whole-body model. Order of magnitude analysis (OMA) says that oscillation is less 
important in oscillatory effect versus convection of blood effect.  
When it comes to physiological (both clinical -in vivo- and experimental -in vitro-) data of 
macronutrients and certain metabolites, there are decades’ worth of studies (mathematical 
equations, plots, data points etc) accumulated in multiple journals, dissertations and books. Here 
are some of the study types identified which have repeatedly been shown throughout the literature 
search. 
Macronutrient concentration over time under postprandial, fasting and exercise ‘conditions’ 
(denoted below as ‘conditions’) of healthy or diseased patients. This study type elaborates on 
macronutrients concentration change once an individual is administered (usually orally) 
macronutrients. For example, in the simplest case, if one is injected pure glucose in the system, 
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that person will experience sharp glucose concentration at the beginning (near time of 
administration, but not exactly t=0 due to blood circulation) and glucose concentration will 
decrease over time due to the body’s glucose utilization and clearance mechanisms.  
Certainly, there are inter-individual variability of how much glucose can be distributed, utilized 
and cleared from the body due to gender, health, age etc. However, the goal of this model is to 
make an ideal healthy patient model and then generalize this model to better understand the 
development and evolution of T2D. Moreover, when a patient consumes a meal, the patient will 
experience that the concentrations of certain macronutrients change as time passes.  
However, one should keep in mind that in uncontrolled environments, no two meals a person eats 
are exactly the same. For instance, people do not eat exactly 40% glucose (carbohydrates), 30% 
palmitate (FFA) and 30% alanine (AA) of 200g of food in every meal, not to mention that there 
are numerous types of carbohydrates (fibers, sugar, lactose…), FFA (poly/mono/ (un)saturated 
FA), AA (leucine, histidine …) and additional nutrients consumed. In the publications studied, 
however, the patients were given controlled amounts of food so that the input was fixed (food 
administered) but the outputs (concentrations of macronutrients) necessarily were variable.  
Using such controlled studies, the research also could simulate the input and output relationship 
as reported in the articles; moreover, the research also could simulate the food administration of 
different composition situations, not having been researched in any of the articles. Likewise, one 
can use different ‘conditions’ other than the postprandial state. There are studies conducted on 
individuals who exercise at different levels (expressed as percentage of VO2max) and duration 
(expressed as time) or those who fast for a certain amount of time. If this model can simulate every 
condition reported in the publications with certain confidence level, the prediction on what a 
human body model will go through will be even more accurate. 
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Blood flow change and flux (uptake and release rate) of macronutrients into and out from between 
blood vessel and organs/tissues/cells under different conditions. The fundamental principles in this 
study type are same as macronutrient concentration versus time study. For example, using a 
controlled meal plan like that mentioned in macronutrient concentration studies discussed above, 
one could also measure how much the blood flow of arterial/venous blood vessels and 
absorption/secretion rates of organs/tissues/cells change: e.g. to measure lactate secretion rate 
when fasting. Also, studies under different ‘conditions’ and blood flow and flux change are 
reported. 
Hormonal level and flux (hormones such as insulin, glucagon, adrenaline etc.) change over time 
under different ‘conditions’. The fundamental principles in this study type are same as 
macronutrient concentration versus time study. This is usually done with the first type of study 
(macronutrient level and flux). 
Specific organs/tissues/cells’ metabolism (concentration and flux of metabolites) under different 
‘conditions’. The fundamental principles in this study type are same as macronutrient 
concentration versus time study. One example is to feed patient a designed meal to measure 
glycogen concentration in liver or muscle.  
Concentration and flux change of macronutrients, metabolites and hormones under ‘controlled’ 
condition. This study type is slight different in that the focus in this research is to find relationship 
between controlled concentration or flux of macronutrients, metabolites and hormones and those 
uncontrolled. For example, hyperinsulinemia is a well performed and recorded study where the 
researchers maintained the level of insulin from basal level to manifolds higher and sought how 
glucose secretion rate is affected. Another example is to infuse glucose at different rate to measure 
insulin secretion rate. This type of research may be reported as concentration vs rate instead of 
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time as observed in the previous study types. This type of controlled study would give this model 
more robustness for parameter tuning. 
Finally, different models have different purposes. There is a saying that all models are wrong but 
some are useful. The most basic (does not mean it is easy) type of model is to simulate 
concentration and flux over time without blood flow or hormonal levels being affected under 
different ‘conditions’. One should keep in mind that when one eats or exercises or in different 
health condition, not only would the basal concentration and flux of macronutrients and 
metabolites would be affected but also the hormonal level, blood flow or oxygen level (which is 
disregarded in this model) would also be affected. In other words, to make a more precise model, 
one should consider all of the factors mentioned. For example, when a person exercises, it will 
affect insulin/adrenaline/glucagon level, which will affect blood flow rate and concentration and 
absorption/secretion rate of macronutrients and metabolites. The effect of glucose on 
concentration/flux of glucagon can be expressed as constitutive equation for simplification or as 
part of ODEs for precise modeling.  





Glucokinase    F6p 
Phosphofructokinase  AMP  Citrate 
Glycogen phosphorylase  AMP  Glucose 
Ga3p dehydrogenase    Glucose 
Pyruvate kinase   F16p Amino acids 
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Pyruvate dehydrogenase    NADH, ACoA (Pi) 
Citrate synthase  AMP   
Isocitrate dehydrogenase    SCoA (Pi) 
AKG dehydrogenase  AMP  SCoA (Pi) 
Citrate shuttle103    PalCoA (Pi) 
Cit_ACoA_OAA (ATP citrate lyase)    PalCoA (Pi) 
ACoA_Mal-CoA (acetyl CoA carboxylase)    PalCoA (Pi) 
FFA_PalCoA (acyl CoA synthase) (Saggerson, 
2008)    Mal-CoA (Pi) 
PalCoA_ACoA (b oxidation)    ACoA (Pi) 
Carnitine shuttle (carnitine acyltransferase)    Mal-CoA 
Gmt_AKG (glutamate dehydrogenase)    FFA 
ACoA_Gmt_NAG (N-acetyl glutamate synthase)  Arginine   
NH4_Crbphos (carbomyl phosphate synthase)  NAG   
Citrulin_Arg (argininosuccinate lyse)  AMP   
(Glucosamine 6 phosphate N-acetyl transferase)  FFA  Glnac (Pi) 
(N-Acetyl glucosamine pyrophosphorylase)  Glucose   
HMG-CoA_Mevl (HMG-CoA reductase)    Mevl (Pi) 
Table 4.2 1 Key enzymes and their regulators  
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4.3 Signaling molecules 
 
 
Figure 4.3 1 GLUT4 translocation via insulin in/dependent pathways   
 
 




There are multiple signal molecules involved in the cascade (transduction) of signals under 
different conditions. The one of the most widely studied cases involves insulin (controlled 
condition) vs physical exercise (different ‘conditions’) signaling effect of GLUT4 translocation 
(this is not part of concentration/flux study type enumerated above because GLUT4 is not a 
metabolite but the end product of signal molecules transduction). GLUT4 can, therefore, be 
thought as part of signal molecule ‘level’.  
GLUT4 translocation is thought to be important because GLUT4 is one of the main transporters 
in a human body and is thought to be responsible for controlling blood sugar level. Transporter 
and channels are proteins which let macronutrients and other chemicals to enter or exit the cells so 
that metabolism can happen. When metabolism happens inside the cells, there are enzymes and 
signal molecules (with transcription ‘level’ activities) which are playing roles. GLUT4, lets 
glucose get in and out from the cell. MTC lets lactic acid to get in and out. However, the reason 
why there has been more study of GLUT4 is because glucose absorption and secretion are directly 
related to GLUT (1 and 4) transporters. Therefore, there are more studies regarding GLUT4 
translocation than any other transporters in T2D studies. Whether GLUT transporters and 
especially GLUT4 are truly responsible for T2D are still open to debate. In this model, even though 
GLUT4’s activity matters in leading to T2D, the primary cause of T2D onset is thought to come 
from visceral adipose tissues. This will be explicated in chapter 12.  
Here are a few more pieces of information on GLUT4. GLUT4 resides in 50-70nm GSV (majority, 
scattered throughout cytoplasm) and larger structures, being derived from trans-Golgi network and 
endosomes. In an effort to identify GSV specifically, insulin-regulated amino peptidase (IRAP) 
was devised. GLUT4 and IRAP are highly colocalized while v-SNARE VAMP2 not in GSV 
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(however, IRAP and VAMP2 are both abundant in GSV). GSV varies in GLUT4 content 
(heterogeneous). IRAP-pHluorin and VAMP2-pHluorin can be used (prior on GSV GLUT4 and 
latter on GSV (56nm) and larger structures (150nm)). Within 3-4 minutes after insulin stimulation 
(insulin burst) IRAP-pHluorin shows rapid fusion of GSV while VAMP2 shows two events (burst-
GSV- and continuous-larger structures-). 
Rate of entry of glucose into cells is regulated by transporters. Blood glucose level is 5mM. Basal 
Glucose transporter in most cells has Km of 1mM. Less than blood glucose and so glucose is taken 
up easily. But in liver and pancreas glucose transporters have Km of ~15mM (close to blood 
glucose levels). This allows pancreatic cells to monitor glucose levels and thereby regulate insulin 
secretion. In liver cells, glucose is only taken up when it is very abundant. Then liver cells acquire 
glucose and convert it to glycogen and fatty acids. 
Putting the controversy concerning GLUT4 aside, two main ways in triggering GLUT4 
translocation will be discussed: insulin and exercise.  
Insulin is more obvious reason for GLUT4 translocation. Insulin is secreted from pancreas when 
glucose (mostly) or AA (low to moderately) sources are detected by the pancreas. Then the 
pancreas releases insulin, which will stimulate certain organs/tissues/cells to absorb glucose. 
This research is going to use an example of muscle and is not going to differentiate various 
muscles in favor of simplicity. 
Muscle absorbs glucose using GLUT4 when insulin binds to its sarcolemmal membrane’s Insulin 
Receptor (IR) α component. This will change conformation of β component of IR, which is 
inside the cell. This will attract Insulin Receptor Substrate (IRS) which will activate PI3 Kinase 
(PI3K). PI3K will then affect PIP2 and PIP3. PIP3 will affect PDK, which will activate Akt. Akt 
will in the end activate AS160 (a.k.a. TBC1D4). AS160 will then affect GLUT4 vesicles to be 
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merged with inner cellular membrane so that GLUT4 can be translocated on the cellular 
membrane. This process is still not entirely known and this research will cite one publication to 
elaborate what are thought to happen during this process. AS160 protein and rest of the process 
taking place is important and interesting because exercise induced GLUT4 translocation happens 
to have the same process (before which the transduction process is different) once it reaches 
AS160. 
In many of the articles, AS160 affecting GLUT4 delivery to membrane surface process is still 
unexplained. It is hypothesized based on [ref] and a publication regarding SNARE protein, that 
AS160 brings the GLUT4 vesicle to the SNARE complex, which is responsible for snatching the 
vesicle and fusing the vesicle with the cellular membrane (Sonntag, Annika G 2012).  
SNARE complex is a protein structure consisting of multiple smaller proteins: VAMP2, Syntaxin-
4 and Munc18-c. When these structures are assembled to form a SNARE complex, the complex is 
responsible for any type of exocytosis behaviors of cells. The reason why it is exocytosis-ish is 
because in GLUT4 translocation, GLUT4 vesicle is snatched by SNARE and the vesicle is fused 
in the membrane so that GLUT4 are placed in the middle of bilayer membrane proteins. That is, 
GLUT4 are not secreted. In case of pancreatic β cells, where SNARE complex snatch insulin 
containing vesicles and fuse them with the β cell membrane, the insulin is secreted. Therefore, this 
is exocytosis-like behavior.  
The articles suggest that GLUT4 vesicle is transported by microtubule then it is transported to 
actin. GLUT4 vesicle has AS160 and VAMP2 imbedded in the vesicle layer alongside Rab and 
GLUT4 proteins, when it is moved to the inner cellular membrane during the transportation. 
Whether AS160 and VAMP2 allure the vesicle to formation of SNARE complex is unknown; 
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however, it is assumed so. After the GLUT4 vesicle approaches the membrane surface, SNARE 
complex is assembled which fuses the vesicle to the cellular membrane.  







































High affinity for 
fructose 
Table 4.3 1 Glucose transporters  
 
The signal molecules listed here have been known to play central role in insulin triggered GLUT4 
translocation. The individual signal molecule’s exact role is still being studied and modified with 
additional proteins being discovered, disregarded and discarded in the transduction process 
meanwhile. There are many studies which say the disruption of certain metabolites, enzymes or 
signal molecules are the main reasons for onset of T2D (experimented by artificially encoding 
genes to be knock-out of certain chemical of interest or measuring the level of certain chemicals 
of interest etc.); however, the onset of T2D is still undetermined. Disruption/alteration in signal 
molecule’s activity/concentration (IR to SNARE complex) may not be because they are the cause 
of T2D but because they may be merely biomarkers of T2D (byproducts as part of the T2D 
process). In other words, there may or may not be correlation but necessarily causation between 
onset of T2D and signal molecule’s activity/concentration deviation (Sonntag, Annika G 2012).  
Another main way for triggering GLUT4 translocation is exercise. The similarity between insulin 
induced translocation and exercise induced translocation, as mentioned briefly above, is that both 
mechanisms share downstream process after AS160 protein is activated. Before the activation of 
AS160, the signal molecules and reactions taking place are different from insulin induced 
translocation. There are a few factors which are thought to cause pre-AS160 process. AMP/ATP 
ratio, ROS (Reductive Oxidative Species), calcium ion, NO (Nitrogen Oxide), temperature etc. 
Unlike insulin induced GLUT4 translocation where multiple signal molecules being involved in a 
single long chain of reactions, exercise induced GLUT4 translocation has multiple (parallel) 
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starting points, hence many short chains of reactions until they reach common convergence, i.e. 
AS160. Everything except AMP/ATP ratio will be explained further in muscle part of this chapter.  
AMP/ATP ratio plays the following role. When one exercises, there will be fluctuations of AMP, 
ADP and ATP concentration. Assuming exercising without consuming any food, at the beginning, 
the residual ATP will be used, then creatine/phosphocreatine (CR/PCR) will generate ATP for a 
short period of time. Afterwards, glycogen storage will release glucose which will be used for 
glycolysis for anaerobic exercise. The first three (residual, CR/PCR and glycolysis) are anaerobic 
by nature and do not need oxygen for production of ATP. As a result of anaerobic exercise, 
pyruvate turns into lactate (oxidation taking place in TCA cycle is not quickly able to utilize 
pyruvate so some pyruvate changes into lactate) and the lactate cannot be used in muscle so it has 
to be released and absorbed by liver. Once absorbed by liver, depending on the necessity, the 
lactate will convert back to pyruvate and can be stored into glycogen or undergo gluconeogenesis 
(especially when exercising) or be used for TCA. This will be explained in chapter 6. Under 
aerobic exercise and resting condition, TCA cycle will have enough time to produce extra 34 ATPs 
utilizing FFA or KB, which will convert to AcCoA and be incorporated into TCA. The definition 
of aerobic and anaerobic will be explained in chapter 6. Either way, ATP will be generated. When 
exercising, ATP will be used for BMR, thermogenesis and exercise. Such extra energy expenditure 
in the form of exercise is to fuel muscle’s movement such as stretch and contraction. Breaking 
homeostasis of AMP/ATP ratio, AMP will increase due to higher energy expenditure when 
exercising. This higher ratio will in turn activate AMPK (AMP Kinase), which is a protein 
responsible for numerous reactions, not just limited to muscle’s exercise induced GLUT4 
translocation. AMPK will activate AS160 and probably the same process mentioned in insulin 
induced GLUT4 translocation will happen.  
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So far, the research has introduced what happen to GLUT4 translocation arising from insulin and 
exercise effects, to explain signal molecule ‘level’. There may be different signal molecule 
reactions happening for glucagon/adrenaline binding on muscle/other organ/tissue/cell receptors 
and under resting/exercise/fasting/postprandial conditions. With limited resources and time, it 
would be challenging to incorporate all of such information into one thesis. However, such 







IRS    PTP, PKC, S6K  
AKT mTORC2 Glnac, TRB3 
PKC   
DAG, Glnac, 
FFA   
GSK3  PP1, Phk  Cal, PKA, FFA  
mTOR  Amino acids    
S6K  Amino acids  AMPK  
TSC  AMPK  AKT 
cAMP  Gprt  PDE3  
PKA  cAMP    
PDE3  AKT PKA  
Table 4.3 2 Signaling molecules and their regulators in GLUT4 transport pathway 
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4.4 Transcriptional level 
In most of the models, transcription level or gene level are not usually described. It is usually 
because simpler models are easier to make and also transcription level are for the long term effect 
which could take up to a few hours. For the modelling purpose, transcription level is not necessary. 
In this model, however, one transcription factor and its gene out of many other transcription level 
chemicals, called Hypoxia Induced Factor (HIF-1) are introduced. Other transcription level 
chemicals and their corresponding genes often found in experimental data in T2D and related 
diseases (such as atherosclerosis, high cholesterol etc.) are FOXO (Forkhead Box Protein), SREBP 
(Sterol Regulatory Element Binding Protein) and CHERP (Calcium Homoeostasis Endoplasmic 
Reticulum Protein) etc. The main reason why such transcription level chemicals and genes are 
related to not only T2D but also other diseases is because many of transcription level chemicals 
and genes share same metabolic pathways for normal human beings. That is, for diseased humans, 
some parts of the transcription level processes in the same metabolic pathway malfunction while 
other processes may or may not function normally. Therefore, SREBP, which is responsible for 
high cholesterol disease due to its cholesterol controlling mechanism, play a role in leading to T2D 
because FFA concentration in T2D patients also change. However, the research would like to 
introduce a transcription factor (HIF-1) which is more unique and thought to be fundamental to 
T2D.  
Two snippets of information regarding HIF-1 and T2D research are introduced here.  
For the first part of the information, it has been long thought that T2D patients are obese and the 
obesity is the driving force for insulin resistance. To further explain how obesity induces insulin 
resistance, research on HIF-1 alteration in adipose tissues and the adipose tissues’ changed 
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metabolism somehow causing insulin resistance were introduced. However, a few weaknesses in 
this explanation pointed out.  
First, the definition of obesity is not clear and there are different types of obesity. In many of the 
old to recent articles, the experiments performed on patients to measure their obesity has been 
surprisingly wrong. An individual is defined to be underweight/lean/overweight/obese depending 
on Body Mass Index (BMI). BMI is a function of height and weight. It is easy to think that for the 
given gender and age and height, if one’s weight is appreciably high, that person is thought to be 
obese. The usual image of obese people is those who have portending belly and with extra fat on 
limbs. This, however, is an image limited to subcutaneous fat. Subcutaneous fat are adipose tissues 
sitting under the skin and is the main reason why people become obese. This type of fat has less 
constriction in terms of how and where it can expand/shrink. However, there are people who look 
lean but in fact are more likely to have T2D and cholesterol related diseases. This group of people 
tend to have more visceral (around organ) fat. This type of fat is relatively more confined in terms 
of movement. Those who possess high visceral fat may have lower BMI. Therefore, it is necessary 
to measure subcutaneous/visceral fat when it comes to T2D studies.  
Second, the conventionally defined obese people do not necessarily have T2D. There are group of 
people who have high BMI but are metabolically healthy. This group of people is called MHO 
(Metabolically Healthy Obese). They, indeed, will be less likely to have T2D or cardiovascular 
related diseases.  
Third, the mechanism in HIF-1 expression altered adipose tissues’ metabolism causing ‘insulin 
resistance (probably muscle)’, ‘energy expenditure’ and ‘β cell glucose intolerance’ needs to be 
understood better (Gunton, Jenny E 2005). One should bear in mind that correlation is not 
causation. HIF-1 may or may not be the direct cause of the listed phenomena, so it is premature to 
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say that HIF-1 is cause. For example, if HIF-1 is the cause of insulin resistance, how the 
metabolism in insulin resistant organs/tissues/cells changes as a result of HIF-1 expression 
alteration in adipose tissues should be thoroughly explained.  
For the second part of the information, there were a few different researches in vivo/in vitro 
experiments on humans and animals to measure HIF-1 level and the corresponding metabolism 
change in different organs/tissues/cells (Girgis, Christian M 2012). However, this also comes with 
a few weaknesses. 
First, in vitro data may not be applicable to in vivo situations. This is well known but oft-
disregarded fact. Up to these days, many researchers use in vitro data to fit their models’ 
parameters. There should be justification and study on how and when in vitro can be used for in 
vivo. 
Second, how the HIF-1 level changes in different organs/tissues/cells under healthy or T2D 
condition is not well understood. HIF-1 level change in different cells extracted from different 
organs/tissues/cells are studied (Wang, Xiaohui L 2009). It is one thing to study individual cell’s 
HIF-1 expression change and its metabolism changes and it is another to study how different cells 
from different organs/tissues/cells affect each other which lead to HIF-1 change and T2D. 
Third, in case of muscle and adipose tissues, the exact definition of them is required. Muscle can 
be categorized in different ways. White muscle and red muscle, active muscle and inactive muscle 
when exercising etc. In many researches, one of the thigh muscle is well studied due to its high 
involvement in motions. If one generalizes muscle, the model result may not be accurate. Same 
goes for the adipose tissues. Subcutaneous, visceral and ectopic fat, white adipose tissue (WAT) 
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or brown adipose tissue (BAT) are very different. Normally, WAT is what we refer to as fat in 
subcutaneous and visceral fats. BAT is near spine, shoulders, neck and back. 
Fourth, adipose tissue acting as a master regulator of bodily metabolism is suggested in many 
articles. An explanation for this may give an answer T2D propagation, which is not available in 
any previous research. This is an extension of the second point of second snippet. Many articles 
point out that fat is the master regulator for body’s metabolism change in T2D and other conditions. 
It is necessary to prove how the adipose tissue plays this role. 
There are several ideas revolving around the onset of T2D. This will be explained in later chapter 
12. The thoughts on how HIF-1 is related to T2D is explained in chapter 12. However, this chapter 
will explain what HIF is first.  
Hypoxia inducible factors (HIFs) are master-regulators of cellular responses to hypoxia, and thus 
are crucial for survival. HIFs also play a role in regulating cellular processes in β-cells, liver, 
muscle, and adipose tissue, have effects on the regulation of weight, and play a role in type 2 
diabetes (T2D). HIF target genes, including genes encoding proteins involved in angiogenesis, 
apoptosis, cell cycle progression, glucose uptake, glycolysis, and lipid metabolism. Composed of 
two parts (α and β – β is called ARNT). Two major risk factors for T2D are insulin resistance and 
β cell dysfunction. Disturbances in HIF-1 signaling may play a detrimental role at several stages 
in diabetic pathogenesis, including the innate failure of β cells to secrete sufficient insulin, insulin 
resistance, adipocyte dysfunction etc (Pillai, Renjitha 2015). 
In pancreas, islets isolated from people with T2D have a 90% decrease in ARNT expression. β cell 
ARNT KO (β ARNT) had reduced glucose tolerance and impaired in vivo and in vitro GSIS, and 
similar changes in gene expression to those seen in T2D islets, including decreased HNF4a, insulin 
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receptor, aldolase, phosphofructokinase and others. β cell culture models (MIN6) shows consistent 
result. Significantly impaired insulin secretion, reduced glycolytic enzyme expression, and 
dysregulation of metabolic pathways. Carbohydrate-responsive element-binding protein (ChREBP) 
as a negative regulator of ARNT and has suggested that ChREBP-mediated repression of the HIF 
complex might contribute to glucotoxicity induced β cell dysfunction. β-HIF-1a null mice had 
severely reduced glucose-stimulated ATP generation and therefore impaired insulin release. VHL 
is required for HIF proteolysis, and thus deletion or inactivating mutations increase HIF protein. 
Interestingly, mice with β cell deletion of VHL have markedly impaired insulin secretion and 
glucose; both depletion of ARNT or HIF-1a and excess of HIF-1a and HIF-2a (with are both 
increased with VHL deletion) impair β cell function, suggesting an ‘inverse U’ relation. Use of 
iron chelators resulted in improved insulin secretion and normalized ARNT mRNA and 
downstream gene expression in islets from people with T2D. Deletion of FIH, which causes 
relatively modest increases in HIFs, also results in improved glucose tolerance in mice challenged 
with high-fat diet (HFD). Human islets from people with T2D have decreased expression of both 
HIF-1a and ARNT, and increasing HIF-1a with iron chelation improved human islet function and 
gene expression (Yamaguchi, Miwa 2015).  
In liver, liver dysfunction is a key component of T2D and is both affected by and contributes to 
the condition. Cardinal features include increased and inappropriate hepatic glucose production 
(HGP) and reduced hepatic insulin sensitivity. Non-alcoholic fatty liver diseases (NAFLD) are 
common in T2D and further exacerbate metabolic dysfunction. It has been shown that feeding 
mice with a high-fat/sucrose diet that causes fatty liver also causes upregulation of hepatic HIF-
1a. When mice with a hepatocyte specific HIF-1a deletion were fed this diet, they exhibited more 
severe impairment of glucose tolerance and peripheral insulin resistance. Consistent with the 
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decrease in ARNT mRNA in T2D islets, ARNT mRNA and protein are also reduced in human 
T2D livers. Short-term hepatic ablation of ARNT in mice using adenovirus injection increased 
HGP and impaired glucose tolerance. Conversely, deletion of hepatocyte VHL substantially 
increased hepatic HIF-1a and HIF-2a proteins and caused life threatening hypoglycemia and 
reduced ketones (Yamaguchi, Miwa 2015).  
In muscle, HIF-1 plays a role in this dynamic process by regulating glycolytic and oxidative 
pathways of energy production, mitochondrial respiration and muscle fiber composition. Its role 
is suggested by three observations: expression is higher in fast twitch muscles that rely on 
glycolysis and is upregulated during bursts of activity and in chronic hypoxia. HIF-1a upregulated 
GLUT4 mRNA after 10 min of electrically induced contraction of isolated soleus muscle; thus 
HIF-1a might facilitate glucose transport following contraction (Yamaguchi, Miwa 2015).  
In adipose tissues, obesity is the strongest acquired risk factor for T2D: it gives a 10-fold higher 
risk in men and 30-fold higher risk in women. Adipose tissue hypoxia, and this appears to drive 
an inflammatory response. In obese humans, reduced oxygen pressures within abdominal fat 
associate with greater macrophage infiltration. Collectively, these observations suggest that (i) 
adipose tissue hypoxia is deleterious and (ii) that defects in the adipocyte response to hypoxia may 
contribute to the pathogenesis of insulin resistance and diabetes. Adipocyte-specific HIF-1a and 
adipocyte-specific ARNT knockout mice report the protection of these mice from the 
consequences of HFD. Specifically, these mice were resistant to weight gain, and had substantially 
better glucose tolerance and insulin sensitivity. Increased insulin-stimulated Akt phosphorylation 
was seen in WAT, liver and muscle in adipocyte specific HIF-1a knockout mice, suggesting 
crosstalk between adipose tissue and other sites. These mice also displayed central effects with an 
increase in core temperature and energy expenditure (Yamaguchi, Miwa 2015).  
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Transcription factors Positive regulation  Negative regulation 
SREBP  S6K, AKT, PKC  cAMP, FOXO, AMPK  
ChREBP Glucose  PKA, AMPK 
PPARg  AKT, FFA  AMPK  
PPARa PKA, FFA, PGC    
CREB  PKA AKT  
CEBPa  cAMP  PKC  
TRB3  
PI3K, PKC, PPAR, 
PGC1   
PGC1 FOXO, CREB  AKT 
FOXO  Glnac, AMPK  AKT, PPARg  
AMPK  AMP AKT, PKA, ATP 
Table 4.3 3 Transcription factors and their regulators   
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5. BLOOD/ECM/ORGAN CELL COMPARTMENT 
 
Figure 5 1 Blood/ECM/Organ compartments  
 
Before going on to organ models and metabolism, how the blood- organs/tissues/cells 
macronutrient/hormone transport is done will be shown. Since metabolites/signal 
molecule/transcription factors are inside the cells of organs/tissues, they are not part of this 
chapter’s discussion. Arterial blood enters organs/tissues and venous blood exits organs/tissues. In 
between the two regimes of blood, there is a cluster of organ cells, capillary and extracellular 
matrix (ECM). In many organ/tissue/cell models, including this research’s, the ‘cluster’ disregards 
ECM, for convenience and it does not cause big errors and most macronutrients in ECM have the 
same concentration to either capillaries or organ cells in different organs/tissues. The capillaries 
inside the ‘cluster’ carry hormones and macronutrients which will be exchanged/react with 
between capillaries and organs’ cells (epithelial cell is the surface cells of the organ). These organ 
cells’ and capillaries altogether are ‘organs’, to be specific, in this model and others, for practical 
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purposes. The concentration of macronutrients inside capillaries are thought to be in 
thermodynamic equilibrium with organ cells at homeostasis. That is, the homeostatic concentration 
of macronutrients in organ cells and capillaries would have constant concentrations. Both 
capillaries and either arterial or venous concentration are assumed to have same concentration for 
simplicity. Postulating that capillary and either arterial/venous concentrations are the same is 
accomplished by assuming tissue to be ideal CSTR (Constantly Stirred Tank Reactor, sudden 
concentration change) rather than ideal PFR (Plug Flow Reactor, axial concentration difference). 
Otherwise, it will be necessary to consider varying concentration inside capillaries spanning from 
the entrance (arterial) to exit (venous) side of organs/tissues. It is true that arterial and venous 
concentration change alongside the axial direction would not matter due to convection where 
capillaries would have less effect in terms of convection, i.e. diffusion and reaction would matter 
more; however, for both simplicity and insignificant errors, one can assume the CSTR condition 
in capillaries (and in fact, organ cells as well). This research, however, further simplifies the 
‘cluster’. The capillaries and the organ cells are altogether forming hypothetical organ 
compartment. This, however, can cause confusion in what concentration of macronutrient one 
should use caused by thermodynamic equilibrium.  
To summarize, one can simplify ‘Arterial Blood → Capillaries, ECM, Organ Cells → Venous 
Blood’ to ‘Arterial Blood → Capillaries, Organ Cells → Venous Blood’ to ‘Arterial Blood → 
Hypothetical Organ → Venous Blood’. In this model, capillaries and organ cells without ECM 
taken into account. This way, this research can differentiate different concentrations in organ cells 




6. DIFFERENT ORGANS/TISSUES/CELLS (BRAIN, LIVER, 
MUSCLE, ADIPOSE TISSUES, PANCREAS, ERYTHROCYTE) 
AND BLOOD CIRCULATION FOR WHOLE-BODY MODELING 
  Rate (μmol/sec, 70kg) 
Hepatic Glucose 
Production 14.35185185 
Total Glucose Uptake 14.35185185 
Brain 6.481481481 
Peripheral (Muscle 










Figure 6.1 1 Brain metabolic pathway 
 
Brain cells are hard to characterize into one type of cell. In many articles, astrocytes and neurons 
seem to be the most popular choices due to their abundance and characteristic metabolism. The 
brain in this model does not play a big role in T2D compared to liver, muscle, adipose tissue and 
pancreas. Therefore, only the basic brain metabolism representing an arbitrary hypothetical brain 
cell will be modelled. Above is brain metabolism schematics found in both astrocytes and 
neurons. Liver normally uses glucose for its fuel but under fasting conditions, it can switch to 
KBs. Other sources of fuels are not able to cross BBB (Brain Blood Barrier); therefore, unlike 
other organs outside the barrier, brain cannot use FFA or AA freely. For absorption of glucose, 
brain uses GLUT2 transporter (no GLUT4 present), which is responsible for facilitated diffusion 
(transporter needed) of glucose. The Km for GLUT2 is lower than GLUT4 so glucose is more 
easily absorbed into the organ (Gjedde, A 1981). 
 
 




Here are some of the issues to keep in mind: Insulin independent translocation of GLUT4 - 
Pathway (Exercise and Muscle). Exercise stimulates GLUT4 translocation in muscle. Exercise 
modality matters (duration and intensity). Both insulin and exercise can increase GLUT4 (recycle) 
and translocation rate (exo- and endo-). Exercise effect can last up to 48 hours (GLUT4 increase 
vs mRNA). Facts and Thoughts: Higher demand for energy during exercise increases AMPK 
(AMP:ATP) which increases GLUT4 translocation. Dilated blood vessel has an increased surface 
area which increases transport of glucose. Given that insulin level will remain the same, insulin 
will impinge synergic effect on increased glucose transport (by dilation) where GLUT4 galore are 
present on sarcolemma due to AMPK level. This may have something to do with GLUCOSE 
SHUNT model (or why does exercise absorb glucose a lot suddenly?) (Kim, Jaeyeon 2006). 
To answer insulin independent translocation of GLUT4 pathway, which was explained briefly 
above as well,  
 






Figure 6.2 3 % of VO2max over exercise intensity 
 
 





Figure 6.2 5 Fuel usage at different exercise intensity 
 
more detailed explanations are given here. There are multiple factors: 
AMPK. During exercise, cellular ATP resynthesis may become insufficient due to lowered levels 
of CP and glucose (what about glycogen and FA?), which increases AMP:ATP. Increase in 
AMP:ATP ratio promotes phosphorylation of LKB1 (aka STK11), which phosphorylates and 
activates AMPK, which phosphorylates AS160. Similar to IDTG, IITG by exercise involves Rab-
GTP protein and TUG. AMPK also phosphorylates HDAC5, promoting the activation of MEF2 
and GEF. These transcription factors are related to GLUT4 expression. In short, AMPK can 
regulate translocation and expression (Xu, Hongyang 2015).  
Calcium. Calcium from sarcoplasmic reticulum via calcium ion pumps will increase energy 
demand and ATP consumption, which increases AMPK and triggers previously mentioned 
cascades (indirect effect). Exercise increasing calcium level vs increasing E demand (order?). 
There is a hypothesis that calcium can directly activate AMPK via CaMKK, independent of energy 
demand (not proven) (Browning, Jeffrey D 2011).  
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ROS. Reactive Oxygen Species (ROS) may be involved in glucose uptake. Administration of 
vitamin E (antioxidants) after exercise on T1D patients attenuated glucose uptake (Chasiotis, D 
1982). 
NO. Nitric Oxide (NO) comes from three NO synthase: iNOS, eNOS, nNOS. NO is related to 
vasodilation of endothelium for nutrient distributions to active muscles, chemical removals and 
homeostasis. Infusion of L-NAME (NOS inhibitor) in exercising humans with 60% VO2max 
(moderate intensity, not low) shows decreased glucose uptake in both healthy and T2D patients 
(no blood flow, insulin and glucose concentration change). However, excessive NO can induce 
insulin resistance via S-nitrosation on β IR, and NO biding on IRS-1 and AKT. Exercise may also 
reduce effect of iNOS (which causes stress and inflammation) (Bolinder, J 2000). 
Muscle temperature. In animals, increase in skeletal muscle temperature stimulated AMPK and 
Akt even after these proteins were inhibited by agents. Exercise induced ROS + NO -> RNS 
provokes a stimulus for translocation. Thoughts. GLUT4 translocation in muscle can be controlled 
by insulin, FFA (lipotoxicity) and exercise etc. Exercise effect on GLUT4 may be by hormones 
(adrenaline…), nerves (sympathetic vs parasympathetic) or mechanics (motions…). Mechanical 
effect of exercise may be due to temperature rise arising from motions and E demand which leads 
to exothermic reactions (Bolinder, J 2000). 
Actin filament. In actin filament (cytoskeleton), there are Rac1 (GTPase) and Myo1c. Exercise 
induces GTP increase which activates Rac1 which is responsible for exocytosis rate (Rab or TUG). 
Myo1c along with numerous other may be involved in translocation (Browning, Jeffrey D 2011).  
Here is some information relevant to exercise. 
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Light, moderate and vigorous activity: One MET, or metabolic equivalent, is the amount of oxygen 
consumed while sitting at rest. Light intensity: < 3 METS. Moderate intensity: 3 - < 6 METS. 
Vigorous intensity: ≥ 6 METS. Glucose utilization and production can be increased more than 3–
4 times without perturbing the arterial glucose concentration. Highly coordinated interaction 
between muscle and liver works to prevent hypoglycemia during exercise.  
‘Glucose Shunt’ concept, most of the increased glucose utilization is shunted to the essential 
organs/tissues/cells during exercise (i.e., skeletal muscle) making glucose uptake by skeletal 
muscle increase by 10-fold. Thus, the plasma glucose utilization in other organs/tissues/cells is 
kept almost constant.  
At rest, liver and heart are primary consumers of blood lactate, while skeletal muscle, adipose 
tissue and ‘‘other organs/tissues/cells’’ produce lactate. Pyruvate exchange occurs primarily 
between skeletal muscle (uptake) and ‘‘other organs/tissues/cells’’ (release) due to its small arterial 
concentration; elsewhere, its effect is negligible. During exercise, lactate release keeps increasing 
in skeletal muscle, while the pyruvate flux changes from net uptake to net release. Only liver 
consumes alanine for gluconeogenesis, while inactive muscles in ‘‘other organs/tissues’’ are the 
main sources in addition to skeletal muscle. Whole-body lipolysis rate is about 2 times greater than 
the whole-body fatty acid oxidation rate, which means that 50% of fatty acids are re-esterified to 
TG. About 15% of re-esterification occurs in adipose tissue and liver takes up the extra fatty acids 
from the blood. Liver utilizes fatty acids as a main fuel. About half of the fatty acids taken up by 
liver are oxidized and half re-esterified to TG. Since adipose tissue lacks glycerol phosphorylase, 
glycerol produced from lipolysis cannot be directly utilized in adipose tissue for triglyceride 
synthesis. Therefore, liver takes up all glycerol produced in adipose tissue, and utilizes it as a 
gluconeogenic precursor and a substrate for TG synthesis. While whole-body lipolysis rate is 
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increased 2–3 fold during exercise, whole-body fatty acid oxidation is increased 3–4 fold. Thus, 
the fraction of fatty acids being re-esterified into TG decreases.  
Besides hormonal activation/deactivation, there are neural activation of metabolic fluxes during 
exercise. For skeletal muscle and heart, calcium is the one of the main activators for metabolic 
reaction fluxes such as glycolysis, glycogenolysis, tricarboxylic acid (TCA) cycle, and oxidative 
phosphorylation.  
Glucagon–insulin ratio affects glycogenolysis and all gluconeogenesis steps in liver. Heart and 
skeletal muscles have no receptor for glucagon, but they can respond to an epinephrine signal 
during exercise. Therefore, the same can be assumed for metabolic flux i (viz., glycogenolysis, 
glucose phosphorylation by hexokinase, lipolysis, and fatty acid oxidation). Lipolysis in adipose 
and GI organs/tissues is modulated by both epinephrine and insulin levels. Secretion of glucagon 
and insulin from the pancreas is affected by blood glucose levels, but during moderate and short 
duration exercise, a direct neural stimulation and blood epinephrine levels are more significant 
because the arterial glucose concentration is almost constant. Blood epinephrine level changes 
with a step increase in work rate according to an empirical relation. In response to a step increase 
in work rate, blood flows in heart (H) and skeletal muscle (SM) increase, while blood flows in the 
gastrointestinal (GI) and liver (LI) organs/tissues decrease. For skeletal muscle, ATP hydrolysis 
rate depends on a work rate (WR) (Kim, Jaeyeon 2006).  
On the other hand, at maximal intensity exercise, the oxygen consumption in heart increases up to 
4 times its resting level. ATP hydrolysis rate applied in each organ/tissue, skeletal muscle 
consumed more than 85% of total ATP production during exercise. Indeed at exercise onset the 
ATP turnover rate in skeletal muscle increased by about 40-fold. Since glycogen is more readily 
available for utilization than fatty acids, the contribution from carbohydrates went up to 95% at 5 
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min from 30% at rest. Shown that exercise activates glucose transport in skeletal muscle by 
stimulating translocation of glucose transporters (GLUT-4) possibly via AMP kinase or calcium 
signaling. It was hypothesized that exercise increases glucose phosphorylation by making 
hexokinase (HK) enzyme bind to mitochondria where HK has an abundant access to ATP and 
becomes less sensitive to product inhibition by glucose-6-phosphate. Carbohydrate utilization 
increases with exercise intensity. While fatty acids utilization is increased for the mild and 
moderate intensity exercise, it is down-regulated at higher intensity (over 65% VO2 max).) (Kim, 
Jaeyeon 2006). 
In human skeletal muscle, a single exercise bout results in increased skeletal muscle GLUT4 
mRNA immediately after exercise (173, 174, 201), and it remains elevated for several hours after 
exercise (173, 174), but appears to return to preexercise levels within 24 h(173). The transport of 
glucose stimulated by insulin or muscle contraction is increased in proportion to the increase of 
GLUT-4, as well as their translocation rate to the cell membranes. This effect may remain for up 
to 48 hours after physical activity, suggesting the need of practice in a chronic manner. Also, 
exercise is critical in the treatment and prevention of type 2 diabetes. Acute exercise activates 
alternative molecular signals that can bypass defects in insulin signaling in skeletal muscle, 
resulting in an insulin-independent increase in glucose uptake. Exercise training results in 























Glycogen 157.8 124.2 115.8 60 
Lactate 1.89 3.45 4.68 8.85 
 
Table 6.2 1 Muscle macronutrient concentration at different exercise intensities 
 
Time 15 Minutes 30 Minutes 45 Minutes 60 Minutes 
Experimental RQ at 59% of 
VO2max 0.96 0.92 0.91 0.9 
 
Table 6.2 2 RQ over time 
 
 
Table 6.2 3 RQ of macronutrients 





Fatty Acid 0.7 
% VO2max Range Exercise Intensity 
90-100% of VO2max Highest Intensity (VO2max) 
80-90% of VO2max High Intensity (Anaerobic) 
70-80% of VO2max High Intensity (Aerobic&Cardio, Probable LT) 
60-70% of VO2max Moderate Intensity (Fat Burning) 





Figure 6.3 1 Adipose tissues metabolic pathway 
 
6.3 Adipose Tissues 
The nutritional trend book named Big Fat Surprise gist is followed. Despite many attempts to reach 
a conclusion on which diet is best for heart/vascular health, a consensus is not made. The US diet 
trend has been the following: Low fat (Total fat consumption being low –caloric content-; food 
pyramid; middle-aged-male-centric; focused on cholesterol level; obesity and T2D increased). 
Transfat (Solidifed unsaturated fat; heart health; cholesterol, obesity and T2D increased). 
Mediterranean (Unsaturated fat should being high-olive oil—caloric content-; obesity and T2D 
unaffected). Atkins (Low carb diet; UNFAO 2008 findings show no correlation between dietary 
fat and heart disease or cancer) (Bolinder, J 2000). 
Here are adipose tissue relevant information. There are concepts of hypertrophy vs hyperplasia. 
Hypertrophy means adipose cells grow in volume as a result of lipid droplet growth while 
hyperplasia means count of adipose cells increase. In humans, hypertrophy is usually a reason for 
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gaining weight. Obese individuals may have hyperplasia too. In some of the hypertrophic cases, 
due to hypoxia, angiogenesis will be induced. However, angiogenesis may not be able to supply 
enough O2 due to large demand of O2 by adipose cells. This may lead to hypoxic fibrosis. MHO 
(Metabolically Health Obese) have less fibrosis, inflammation and visceral fat and improved 
glucose and lipid homeostasis and smaller adipose tissues (compared to non-MHO obese). 
Increased expandability-less fibrosis- vs increased adiposity-smaller adipose tissues-. Paradox is, 
whichever the cause for MHO phenomenon is, MHO may get healthier as they get more obese.  
Adipose tissues are master communicator with other organs/tissues/cells. Nutritional, Neural 
pathways, Adipokines are methods adipose tissues use to communicate. Nutritional. This is 
because of lipid metabolism during fasting/postabsorption. Neural pathways. This is because of 
sympathetic-lipolysis- and parasympathetic, communication to brain for leptin sensitivity (in mice) 
via afferent nerves. Adipokines. These include autocrine, paracrine, endocrine such as TNF-a and 
leptin.  
Insulin effects fat to be stored in WAT and BAT to reduce energy expenditure by 50%. When the 
body goes through ketogenesis due to fasting, more BAT could be produced (beige). Ceramides 
and sphingolipids may be more responsible for IR progression, not TAG.  
There are multiple lipases and proteins involved in adipose tissue metabolism. ATGL (Adipose 
Triacylglyceride Lipase). This is related to transcriptional level regulation (-2hr) by insulin and 
post-transcriptional level regulation by perilipin-1, which is also regulated by insulin- via cAMP. 
HSL (Hormone Sensitive Lipase). This lipase is acutely affected by insulin via cAMP. MSL 
(Monoglyceride Sensitive Lipase). This is acutely affected by insulin via cAMP. LPL (Lipoprotein 
Lipase). This is affected by insulin as well. Perilipin. This is acutely affected by insulin via cAMP 
(Bolinder, J 2000). 
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7. RELEVANT DATA 
Here is science of fasting and weight loss. Ghrelin-hunger hormone. HGH-sparing protein, 
mobilizing FA. Insulin-dependent lipolysis. Ketone Bodies-fasting. Leucine-protein synthesis. 
When low carb diet: metabolism down, muscle loss. When fasting: metabolism up, fat loss. 
Resting energy expenditure increases in early starvation, accompanied by an increase in plasma 
norepinephrine. This increase in norepinephrine seems to be due to a decline in serum glucose and 
may be the initial signal for metabolic changes in early starvation.  
Energy requirement per day is calculated in this research. 1TAG -> 3FA + Glycerol is assumed. 
Assuming that a human body needs fat as the only external food source for daily BMR, the 
following calculation can be done. BMR: 1500 [kcal/day], FFA energy content: 9 [kcal/g], palmitic 
molecular weight: 256.42 [g/mol]. A daily BMR FFA uptake requirement is assumed 1500/9 
[g/day] = 166 [g/day]. Then one can change the aforementioned requirement to moles for ratio 
comparison: 1500/9/256.42 [mol-FA/day]. Assuming 2 glycerols become 1 glucose (GNG), TAG 
breakdown can be thought to produce 6FA and 1 glucose. 1500/9/256.42*(1/3)*(1/2) [mol-
glucose/day]. By reverting to weight scale for understanding: 180 [g-glucose/mol]* 
1500/9/256.42*(1/3)*(1/2) = 19[g-glucose/day], can be obtained. As a daily glucose requirement 
by organs/tissues/cells, especially for erythrocytes is 14.4 [g/day], maybe rest of the glucose is 
used for other organs/tissues/cells. The remaining glucose can be possible cause of dawn 






8. FATTY ACID TYPES AND METABOLISM  
NAFLD (non-alcoholic fatty liver disease). Serum FFA profiles of NAFLD patients were 
significantly higher compared with HC, and obese NAFLD patients presented the poorest FFA 
profiles. Furthermore, 14:0 (myristic acid) and 16:1 (palmitoleic acid) are of promising diagnostic 
value in the early diagnosis of NAFLD especially among normal weight individuals. 
Elevated serum 16:1 profile is also significantly related to abdominal adiposity and fatty liver 
disease (FLD). A rich source of 14:0 has been reported to acutely raise LDL levels. Beneficial 
effect of Mediterranean diet in improving cardio-metabolic health and plummeting cardiovascular 
related morbidities and mortalities has been reported. (Presumably) Down-regulating the action of 
7α- hydroxylase (a rate limiting enzyme in bile synthesis and cholesterol regulation), thereby 
increasing fecal excretion of cholesterol. Both 14:0 and 16:1 can be derived from diets and whether 
their dietary intakes were associated with serum levels were not studied (Bolinder, J 2000). 
Here are lipoprotein miscelle studies regarding consumption of nutrients: Higher intakes of 
saturated fatty acids leads to higher LDL cholesterol, higher HDL cholesterol, lower triglycerides, 
lower total cholesterol-to-HDL cholesterol ratio. Whereas increased carbohydrate intake causes 
lower LDL cholesterol, lower HDL cholesterol, higher triglycerides, higher total cholesterol-to-
















y (cal %) 
Standard American Diet (SAD) 2200 275 (50) 82.5 (15) 85 (35) 
Paleolithic Diet 1388 129 (39) 92 (27) 46 (28) 
Mediterranean Diet 1823 211 (47) 88 (20) 59 (28) 
Ketogenic Diet (Similar to Early Atkins 
Diet, Low Carb) Variable 13 (5) 52 (20) 87 (75) 
 
Table 8 1 Different diets’ macronutrient composition 
  14:0 16:1 Total Fat 
BMI + + + 
Body Fat + + + 
Fasting 
Insulin + + + 
TAG + + + 
HDL NS NS NS 
LDL + + + 
 
Table 8 2 Different fatty acid types and associated biomarkers 
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9. GLUCOSE AND FFA CORRELATION WITH MORBIDITY 
AND CARDIAC HEALTH 
The research will introduce some literature where ‘what is believed to be true of a relationship 
between certain macronutrient and certain disease’ contradicts to ‘what the real correlation is’. 
These revelations are instrumental and insightful in understanding T2D and many other diseases 
of interest because they tell us that one should aim for finding out the root cause rather than 
superficial correlations. In Lancet paper, there was a study on total mortality and major 
cardiovascular disease depending on consumption of two types of energy source/nutrients: fat and 
carbohydrate. In ‘Food Pyramid’ and many of the worldwide food guidelines say that high 
carbohydrate diet is more desirable so that cutting down fat’s content in food as much as possible 
would be good for preventing diseases such as stroke, atherosclerosis, cardiac arrest, high 
cholesterol, high pressure etc. According to ‘Big Fat Surprise’, the high carbohydrate diet and high 
carbohydrate based Food Pyramid has not done a good job in reducing mortality, T2D and 
cardiovascular diseases. It says that Mediterranean diet (berries and nuts) did not improve nor 
exacerbate the mortality, T2D and cardiovascular diseases. On the other hand, Atkins and 
ketogenic diet (low carbohydrate and high fat) reduce T2D and cardiovascular disease risk. The 
book concludes that dietary fat consumption does not lead to cardiovascular diseases and having 
less carbohydrate helps to reduce the risk. Likewise, the Lancet paper concludes from its meta-
studies that any kinds of fat including saturated and mono/polyunsaturated fat are positively 
correlated with decreasing both mortality and cardiovascular disease risk while carbohydrate is 
negatively correlated. Both the book and the article indicate that if one is to consume same amount 
of calorie for everyday activity (BMR + digestion + optional exercise), reducing the percentage of 
carbohydrate contribution of energy % (not weight %) is good for health. The increase in fat energy 
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contribution % is not only enough for survival (to live) but also maintaining health without major 
health risks (to live healthy).  
This is counterintuitive to a widely held belief that high fat related diseases such as high cholesterol 
(non-HDL) and atherosclerosis. According to Big Fat Surprise, to treat high cholesterol, people 
used drugs to lower the cholesterol level regardless of density; this brought about declining health 
for women and children. Atherosclerosis has been thought to be caused by fat consumption due to 
the white sticky plague narrowing and hardening the blood vessel without fully understanding the 
mechanism. T2D, likewise, has been blaming obesity as the main reason of T2D progression. In 
this case visceral fat depot around organs, not dietary fat nor high BMI due to subcutaneous fat, 
may be responsible for the onset.  
In a nutshell, it is needed to figure out the causation not correlation when it comes to disease. 




10. EFFECTS OF HORMONES 
There are different insulin increase effects on glucose.  
1. Insulin sensitive organs/tissues/cells by direct action.  
This increases glucose transport in muscle, adipose tissues but not in liver. Muscle and adipose 
tissues glucose transport = non-equilibrium (kinetic). liver glucose transport = near equilibrium 
(thermodynamic). Muscle and adipose tissues deploy more GLUT4 onto the surface (perhaps by 
SNARE). 
Increases glycolysis by increasing activities of HK (to G6P), 6PFK (to F6P) in muscle and adipose 
tissues. HK by perhaps by signal pathway, 6PFK perhaps by signal pathway + F-2,6-P. 
Increases glycogenesis in adipose tissues (direct), muscle and liver (direct? + indirect). If glycogen 
in adipose tissues is replete, excessive carbon is stored as lactate and delivered to liver for indirect 
glycogenesis. Glycogenolysis may be more sensitive than glycogenesis (Marchand, I 2002). 
2. Insulin sensitive organs/tissues/cells by indirect action. 
Mobilization of adipose tissues affects intestines and brain metabolism indirectly.  
There is insulin increase effects on FA. Decreases FA lipolysis in adipose tissues, hence, lower 
plasma FA. Increases FA and TAG synthesis in T. Increases VLDL synthesis in liver. Increases 
TAG uptake in muscle and adipose tissues. Decreases HSL (TAG breakdown) activity and 
increases LPL activity (TAG absorption) + plus. 
There is insulin increase effects on glucose and FA. β oxidation of FA inhibits glucose transport 
and glycolysis. If insulin increases, HSL activity is inhibited as a result of cAMP activity decrease 
(signal pathway) in adipose tissues, plasma FA decreases and less FA into muscle at the same time 
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when malonyl-CoA inhibits FA oxidation. HSL activity decreases in adipose tissues so Less FA 
into muscle and Malonyl-CoA inhibits β oxidation. Here is the reaction of malonyl-CoA 
production.                  AcCoA + ATP + CO2     ->    malonyl-CoA + ADP + Pi. 
However, now it is suggested that it may not be β oxidation that inhibits glucose transport but 
excess FA in muscle may interfere with signal pathway of insulin (PI3K activity decreases as a 
result of IRS-1 interference), to be explained. Lipotoxicity in pathogenesis of T2D and glucose 
intolerance. HSL and LPL becoming less sensitive to insulin may cause lipotoxicity. Perhaps this 
may lead to excess FA in muscle. In the end, higher organ/tissue/cell and plasma FA will impact 
muscle, liver and pancreas. 
Blood flow increases as a result of endothelium derived nitric oxide (perhaps glucose transport 
increases as well). It can be secreted by cholinergic (vagus nerve stimulation) when fed, a non-
nutrient secretagogue. AA promotes both insulin (proteogenesis) and glucagon.  
Acute exercise may lead to more GLUT 4 on sarcolemmal membrane, while chronic exercise may 
lead to higher GLUT 4 mRNA expression, higher insulin sensitive signaling (talk of mechanistic, 
hormonal, nervous). Also, glycemic index (GI) for different carbohydrates may be important for 
insulin secretion profiles. 
Carbohydrate metabolism:  It increases the rate of glucose transport across the cell membrane in 
muscle and adipose tissue. It increases the rate of glycolysis in muscle and adipose tissue by 
stimulating hexokinase and 6-phosphofructokinase activity.  It stimulates the rate of glycogen 
synthesis in a number of organs/tissues, including muscle, adipose tissue and liver. It also 
decreases the rate of glycogen breakdown in muscle and liver.  It inhibits the rate of glycogenolysis 
and gluconeogenesis in the liver. 
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Lipid metabolism: It decreases the rate of lipolysis in adipose tissue and hence lowers the plasma 
fatty acid level. It stimulates fatty acid and triacylglycerol synthesis in organs/tissues/cells. It 
increases the rate of very-low-density lipoprotein formation in the liver.  It increases the uptake of 
triglyceride from the blood into adipose tissue and muscle. It decreases the rate of fatty acid 
oxidation in muscle and liver. It increases the rate of cholesterol synthesis in the liver. 
Protein metabolism:  It increases the rate of transport of some amino acids into organs/tissues/cells. 
It increases the rate of protein synthesis in muscle, adipose tissue, liver and other 
organs/tissues/cells. It decreases the rate of protein degradation in muscle. (and perhaps other 
organs/tissues/cells). It decreases the rate of urea formation. 
There are glucagon effects on glucose as well.  
Glucagon signals that blood glucose concentration is low and organs/tissues/cells respond by 
mobilizing stored energy via glycogenolysis, mobilization of FA and gluconeogenesis; inhibits 
glycogen synthesis and glycolysis and binds to receptors in adipose tissues activating lipase which 
mobilizes FFA and glycogen 
Epinephrine does the following. 
When released into blood to prepare the organs/tissues/cells for fight or flight response; binds to 
receptors that are found primarily found in muscle, adipose tissues and liver. In liver, epinephrine 
activates gluconeogenesis and glycogen phosphorylase and simultaneously inactivates glycogen 
synthase by cAMP phosphorylation cascade. Glycogen stores are mobilized increasing blood 
glucose concentration; promotes glycolysis and FA from adipose tissues. 
Cortisol does the following. It is asteroid hormone that signals long term stress such as fear, pain 
or low blood glucose levels; acts on liver, muscle and adipose tissues; slow acting hormone that 
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alters metabolism by changing metabolic enzyme gene expression; especially good at stimulating 
adipose tissues to release FFA from TAG (cortisol passes through the gene for it is lipophilic). It 
stimulates the breakdown of muscle proteins and increases the rate of export of AA to the liver for 
gluconeogenesis by increasing pyruvate carboxylase in the liver (Matthews, D. R 1985).  
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11. DIFFERENCE BETWEEN HEALTHY AND T2D PEOPLE 
In this section, the difference between healthy and T2D people is addressed. One of the biggest 
difference is gluconeogenesis rate. In healthy people, gluconeogenesis rate always is kept constant.  
However, in T2D people, twofold increase in rates of glucose production attributed to an increased 
rate of gluconeogenesis.  
When characterizing T2D, one normally thinks of insulin resistance (IR). The definition, 
mechanism and characteristics of IR is explained in the next section. In this research, it is thought 
that sugar production being another characteristic of T2D, in addition to IR. T2D revolving around 
IR concept says that glucose level is high due to incapability of normal pancreas to release 
excessive insulin to compensate for hyperglycemia. IR people who can secrete excessive insulin 
to compensate for hyperglycemia will be NGT (Normal Glucose Tolerant) people, not T2D. 
However, given the facts that T2D people experience dawn phenomena, one also needs to think 
about sugar production being another characteristic of T2D. Dawn phenomena is defined as 
overproduction of glucose between the midnight and 8am (overnight sleep). This raises blood 
glucose level in T2D and some healthy people without food consumption without apparent reasons. 
The glucose level decreases to T2D baseline once breakfast is consumed as insulin is released. 
This phenomenon cannot be explained by merely IR. Eventually, one can think of following 
questions. For NGT IR patients, does insulin increase accordingly to glucose level, above normal 
level (excessively) for compensation? If so, β cells may have very high capacity to compensate for 
sugar overproduction (proven in in vitro β cell glucose infusion experiment). For T2D people, can 
normal pancreas release excessive insulin but still has hyperglycemia? If so, T2D patients may 
have both IR and sugar overproduction, although their contribution may be different in different 
people (Matthews, D. R 1985). 
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Here are more facts and comparison regarding healthy and T2D people.  
In liver, the following happens. Increased free fatty acid delivery, and reduced VLDL catabolism 
by insulin resistant adipocytes, results in increased hepatic triglyceride content and VLDL 
secretion (Hetherington, J 2011). This may lead to NAFLD.  
In muscles, the following happens. Muscle develop insulin resistance 10 years before type 2 
diabetes kicks in. Muscle glycogen synthase dysfunction is thought to be responsible for IR more 
than any factors. Gulli et al. (32) were the first to demonstrate that the NGT offspring of two type 
2 diabetic parents demonstrated marked muscle insulin resistance but normal sensitivity to the 
suppressive effect of insulin on hepatic glucose production. However, a normal basal rate of HGP 
in the face of fasting hyperinsulinemia could be construed to indicate the presence of hepatic 
insulin resistance. The development of hyperglycemia further stimulates β cell secretion of insulin, 
and the resultant hyperinsulinemia causes a downregulation of insulin receptor number and of the 
intracellular events involved in insulin action, thus exacerbating the insulin resistance. In some 
individuals, the persistent stimulus to the β cell to oversecrete insulin leads to a progressive loss 
of β cell function. After 72 hr of sustained physiologic hyperinsulinemia, insulin stimulated muscle 
glycogen synthase activity, total body glucose uptake, and nonoxidative glucose disposal 
(primarily reflects glycogen synthesis in muscle) were significantly reduced in health people. 
Taken together, these findings indicate that hyperinsulinemia is not only a compensatory response 
to insulin resistance, but also a self-perpetuating cause of the defect in muscle insulin action 
(Matthews, D. R 1985). 
Meanwhile for adipose tissues, the following happens. In insulin resistance the effects on adipose 
tissue are similar, but in the liver the increased free fatty acid flux tends to promote hepatic very 
low density lipoprotein (VLDL) production whilst ketogenesis typically remains suppressed by 
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the compensatory hyperinsulinemia. Furthermore, since lipoprotein lipase activity is insulin-
dependent and impaired by insulin resistance, peripheral uptake of triglycerides from VLDL is 
also diminished. These mechanisms contribute to the observed hypertriglyceridemia of insulin 
resistance. In addition to free fatty acids, adipose tissue secretes a number of cytokines which have 
systemic effects on insulin resistance. Adipocytes from diabetic and insulin resistant individuals 
have reduced GLUT 4 translocation, impaired intracellular signalling via reduced IRS-1 gene and 
protein expression, impaired insulin-stimulated PIP-3 kinase and Akt (protein kinase B) (Sonntag, 
Annika G 2012). 
In general, the following is known. The majority of type 2 diabetic subjects are obese, they also 
have daylong elevation of the plasma free fatty acid (FFA) concentration and increased circulating 
levels of inflammatory cytokines. Because elevated plasma glucose, FFA, and cytokine 
concentrations all can induce insulin resistance, it is extremely difficult to separate the contribution 
of each of these metabolic defects in the pathogenesis of type 2 diabetes. Initially, it was assumed 
the mechanism was a competition between fatty acid and glucose oxidation, the so-called Randle 
cycle, but a much more complex effect of fatty acids on insulin signaling has evolved. One concept 
is excess fatty acids interfering with insulin signaling via PKC induced serine phosphorylation of 
IRS-1 with support for that idea that PKC-theta knockout mice are resistant to fat-induced insulin 
resistance. The elevated fasting plasma FFA concentration in the presence of fasting 
hyperinsulinemia and the impaired suppression of plasma FFA during the euglycemic insulin 
clamp. These findings indicate the presence of marked adipocyte resistance to the antilipolytic 
effect of insulin. Impaired insulin-mediated suppression of whole-body lipid oxidation also was 




12. RECAP ON T2D PROGRESSION WITH THOUGHTS ON HIF 
Before starting this section, some terms and relationships need to be defined clearly. Lean and 
obese. NGT (Normal Glucose Tolerant), IGT (Impaired Glucose Tolerant) and T2D. Nondiabetic, 
prediabetic and diabetic. Insulin resistant (IR) and insulin sensitive. First, lean and obese are 
determined by several measures including BMR, waistline etc. Second, NGT, IGT and T2D 
indicate how high the blood glucose level is. NGT people will have normal glucose level while 
T2D will have fully developed hyperglycemia. IGT people have higher glucose level than NGT 
people but lower glucose level than T2D.  Third, nondiabetic, prediabetic and diabetic are 
interchangeable terms with NGT, IGT and T2D respectively. Last but not least, insulin resistant 
means for the same glucose to be absorbed, higher insulin level is needed. Healthy people are 
usually insulin sensitive (normal insulin level lets glucose to be absorbed without hyperglycemia) 
(Bolinder, J 2000).  
One thing to keep in mind is that prediabetic/T2D people do not necessarily have β cell dysfunction 
[ref]. β cell still can release more insulin to compensate for higher glucose level up to a certain 
point in insulin resistant people. Hyperinsulinemia is another feature of prediabetic and T2D. 
Hyperinsulinemia, in turn, may reduce insulin receptors in different organs/tissues/cells which can 
further exacerbate glucose intolerance (Sonntag, Annika G 2012). This may cause β cell 
dysfunction in the final stage, but not necessarily. 
Given the information, this research concluded that there are several possibilities of disease states. 
By categorizing three groups, lean/obese (1st), NGT/IGT/T2D (2nd) and IR/non-IR (3rd), one can 
hypothesize and test what may happen to people of different health conditions. In one experiment, 
a group of patients, who were offspring of T2D parents, were lean, NGT and IR. This means, 
genetically T2D disposed offspring did not have high BMR and had normal glucose level but had 
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IR. Their pancreas secretes more insulin, as a result, to compensate for IR to keep glucose level 
desirable. This also corroborates the fact that β cell is not necessarily broken down (Sonntag, 
Annika G 2012).     
Recent research suggests that the possible cause of insulin resistance (IR)/T2D initiates from the 
muscle. However, there are two competing ideas on which may be the exact starting point: One 
suggests T2D starting from mitochondria in muscle and the other suggests that it starts from 
lipotoxicity in myocytes’ cytoplasm (Sonntag, Annika G 2012). The explanations regarding these 
are followed below. 
First, an idea that IR/T2D is caused by muscle’s mitochondrial genes for prediabetic and T2D 
people suggest the following. Mitochondrial energy generation related genes are underexpressed 
causing malfunction in β oxidation in mitochondria. Genes involved in TCA, oxidative 
phosphorylation and glycolysis are suppressed. β oxidation is a reaction where FFA absorbed into 
muscle cells producing 8 AcCoA as products, where AcCoA can be used as a substrate for TCA. 
This leads to less oxidized FFA and then higher lipid level in muscle leading to lipotoxicity. The 
difference in energy generation between non-prediabetic (genetically not predisposed) and 
prediabetic (showing IR but not T2D, genetically predisposed) is 90% : 5% (Bolinder, J 2000). 
Second, there is an idea that IR/T2D is cause in muscle by lipotoxicity in prediabetic and T2D 
people. Lipotoxicity causes serine phosphorylation which downregulates tyrosine phosphorylation 
on IRS-1 alongside PI3-K and Akt somehow being affected as well. Glucose transfer and 
nonoxidative glucose disposal (i.e. glycogenesis) are downregulated. Plasma glucose and FFA is 
higher in prediabetic NGT (Normal Glucose Tolerance) IR and T2D people. Such high levels of 
FFA will be absorbed into muscle more readily. FFA, its derivatives and other types of fat such as 
palmitoyl carnitine (a product of CAT reaction and precursor for mitochondrial β oxidation) or 
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DAG (diacylglyceride) may cause disruption in muscle cells. It is thought that lipotoxicity may 
cause downregulation of mitochondrial energy generation genes in the end. Chronic lipid exposure 
in healthy people correlated with decline in insulin dependent glucose uptake and tyrosine 
phosphorylation. It may be due to less GLUT 4 deployment (Bolinder, J 2000). 
Here is a recap on signal molecular cascade. Insulin binds to insulin receptor (IR) α portion. Then 
β IR site undergoes conformational alteration due to autophosphorylation on tyrosine. Then the 
phosphorylation of IRS (IR substrate) -1 and IRS-2 follow. Then IRS-1 and IRS-2 activate PI3K. 
Then PI3K catalyzes phosphorylation of membrane phosphoinositides to produce 
phosphatidylinositol-3,4,5-phosphate. Phosphatidylinositol-3,4,5-phosphate regulates the activity 
of PDK-1. PDK-1 phosphorylates protein kinase B/Akt at Ser/Thr. Akt activates AS160. AS160 
has two significant ways on GLUT4 translocation. First, AS160 reduces the tethering of the GSV 
by acting on TUG protein (pull), releasing GSV to the periphery. Second, AS160 increases the 
activity of Rab proteins which will stimulate (push) translocation of GSV. Previously described 
insulin dependent signal pathway involves microtubles which may be caused by Rab. Then the 
microtubles approach actin filaments, tossing the GSV. By tethering, the GSV is navigated towards 
plasma membrane. By docking and fusion by SNARE complex, the GSV is finally fused on the 
membrane. This last process caused by AS160, in short, translocate GLUT4 onto the membrane 
by 5-30 folds by following possible mechanisms: GLUT4 GSV exocytosis rate constant increases 
(maybe Rab), GLUT4 endocytosis rate constant decreases (maybe TUG). Some also suggest that 
GLUT4 in the cell surface recycling pool increases (due to endosome and Golgi complex). T2D 
patients tend to have dysfunction in one of the molecular reactions (Bolinder, J 2000).  
Combining muscle IR/T2D onset idea and signal molecular cascade, one can conclude the 
following. Various lipid metabolites, including ceramide, DAG, and long-chain acyl-CoA species, 
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are believed to induce insulin resistance (48) secondary to activating Ser/Thr kinases (e.g., JNK, 
mTORC1, IKK) that catalyze site-selective Ser phosphorylation of the insulin receptor and IRS-1, 
resulting in attenuated insulin signaling via IRS-1/PI3K, Akt, and other key steps (Sonntag, Annika 
G 2012). 
In addition to the aforementioned possible causes of IR/T2D, the following is suggested. It is 
thought that there is even more fundamental cause of IR/T2D, which arise from visceral adipose 
tissues. From NAFLD study, it was found out that high levels of FFA (14:0 and 16:1) are relevant 
to having NAFLD no matter they are lean or obese. When a person has NAFLD, they also tend to 
have high level of visceral adipose tissues. Also, high level of adipose tissues is known to be 
associated with T2D. High level of hypertrophic adipose tissues has several characteristics 
including fibrosis, inflammation, higher FFA release and hypoxia. Hypoxia causes HIF molecules 
to increase in visceral adipose tissue which increase adipokine secretion, FFA secretion and cause 
inflammation in adipose tissues. This unique feature is distinguished from subcutaneous fat where 
hypoxia is not of much issues. The diet which causes 14:0 and 16:1 level to increase are not yet 
known. It is thought that lower BMR, lack of exercise and diet may cause visceral adipose tissues 
to build up (Bolinder, J 2000).   
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13 MATHEMATICAL SETTINGS AND METHODS FOR 
WHOLE-BODY MODEL 
13.1 Introduction  
(1) The pathway for specific organ is defined. 
Also known as network reconstruction. Each organ has different metabolite profile. How to build 
metabolite pathway model for different organs and how to connect them will be explained.  
(2) The flux balance analysis is conducted.  
Flux Balance Analysis (FBA) is a linear algebraic calculation with linear constraints considered. 
Usually one can set an objective function and adjust reaction fluxes within constraints using linear 
programming. This can be achieved in many different programming languages.  
How to build stoichiometric matrix and how to calculate steady state flux is explained. Why matrix 
form is informative is discussed.  
(3) Detailed kinetic for each enzyme is written down. 
Flux is the rate of chemical reaction so for each flux one can rewrite as it a reaction rate equation 
depending on metabolite’s concentration.  
The form of equation depends on the enzyme kinetics. Different kinds of enzyme kinetics and 
cofactor or hormone that will affect the enzyme will be explained. 
(4) The simulation with random parameters which satisfy the steady state is performed. 
The condition of this model is changed. For instance, the initial condition of the model is changed 
and whether the model still make sense is observed. 
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(5) The parameters are optimized. 
Here, a strategy to optimize the parameters is developed. 
(6) The model is validated and sensitivity analysis is performed. 
Once the optimization process is over, validation should follow. The data set used for optimization 
for parameter estimation must be different from the data set used for validation. If the same data 
set are used for both optimization and validation, overfitting can happen. Validation is needed to 
see if the estimated parameters are working properly. If optimized parameters are fairly correct, 
the error between simulated plots and the real validation data would be minimal. In this model, 
since there are a plenty of different types of data set, the data sets can be split 50/50 for optimization 
and validation purposes.  
(7) Different organ model will be combined to make a whole body-model.  
 




13.2 Step 1: Reconstruct the metabolite pathway 
The metabolic patterns of the brain, muscle, adipose tissue, and liver are very different. This is 
fundamentally caused by different organs having different metabolites as well as different 
pathways. 
Metabolites and enzymes involved in a reaction has been found in databases such as KEGG and 
Reactome (Rolfsson, Ottar 2011).  
General human metabolic pathway has been developed by using a lot of mathematical approaches 
to reconstruct the complete metabolic states in humans. The most widely referred and cited one is 
Recon 1 (2002, Palsson et al).  
Step for defining a human specific organ model: 
1 draft reconstruction (bottom-up). There are now many different reconstructions published. From 
the very complicated and comprehensive generic information about metabolic function human 
model, special reaction is manually identified. 
2 Manual curations for target organism. Examination of the ‘standard’ reaction and tailoring it into 
specific organs. Then, curation process for different organs is conducted. Obtaining the details of 
co-factor and physiological data that are available for the enzyme.   
3 Some steps are needed to be lumped and this model is simplified because a good compromise 
between biological complexity and the simplicity needed for understanding and practical use 
should be found. For this model, all the rate determining steps and all the important choke points 
are kept. Quasi-Steady-State and Quasi Equilibrium Approximations (fast equilibrium will 
disappear) are used to simplify this model. 
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How these two approximations applied to this simple system are shown in figure 14.2.1 (Sa stands 
for ATP) 
 
Figure 13.2 1 Reaction system  
 
The differential equation can be written as: 
𝑑𝑠1
𝑑𝑡
= 𝑣𝑜 − 𝑘1 ∗ 𝑠𝐴 ∗ 𝑠1 
𝑑𝑠2
𝑑𝑡
= 𝑘1 ∗ 𝑠𝐴 ∗ 𝑠1 − 𝑘 + 2 ∗ 𝑠2 + 𝑘 − 2 ∗ 𝑠3 
𝑑𝑠3
𝑑𝑡
= 𝑘 + 2 ∗ 𝑠2 − 𝑘 − 2 ∗ 𝑠3 − 𝑘3 ∗ 𝑠𝐴 ∗ 𝑠3 
𝑑𝑠4
𝑑𝑡
= 𝑘3 ∗ 𝑠𝐴 ∗ 𝑠3 − 𝑘4 ∗ 𝑠4 
equation 13.2.1 
That all reactions happen on a similar time scale is assumed, meaning that all the reaction rate 
constants (k) are on the same orders of magnitude.  
Set k+2= k-2 = 2 and all other rate constants and the ATP concentration (sA) to values of 1 
(arbitrary units). For time 0-5, system input flux should be vo = 2; then, the flux drops to vo =1.  




 Figure 13.2 2 Results from the original model all k=1  
 
Quasi-steady-state approximation: If the k1 increased to 5, glucose will be rapidly converted to 
g6p. Thus, it will adapt to the input flux change almost instantaneously. The glucose concentration 
at each time point is replaced by the steady-state value s1= v0/(k1*sA), substituting the differential 
equation of s1. Then all s1 concentrations appear in the following differential equations in equation 
13.2.1. Here’s the simulation result with (dash like) and without (solid) the assumption. 
 
 
Figure 13.2 3 Results from the model with fast glucose turnover rate 
k1=5 (solid lines) and the quasi-steady-state approximation (broken lines) 
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Quasi-equilibrium approximation: A rapid and reversible conversion between the G6P and F6P is 
considered. Keeping their ratio Keq= k+2/k-2. In the simulation, the ratio of F6P to G6P levels 






= 𝑘1 ∗ 𝑠𝐴 ∗ 𝑠1 − 𝑘3 ∗ 𝑠𝐴 ∗ 𝑠3 
equation 13.2.2 
Given s2 +3 and Keq, now s3 = s2+3 * Keq/(1+ Keq) is substituted in  
𝑑𝑠4
𝑑𝑡
= 𝑘3 ∗ 𝑠𝐴 ∗ 𝑠3 − 𝑘4 ∗ 𝑠4 
equation 13.2.3 
and a simplified differential equation system in which the fast reaction has disappeared is obtained. 
The two differential equations for s2 or s3 are replaced by a single differential equation. Here is 
the simulation result with (dash line) and without (solid) the assumption. 
 
Figure 13.2 4 Results from the model with fast reversible conversion  





13.3 Step 2: Flux Balance Analysis 
For one very simple system.  
 




When this system reaches steady state, the concentration of x1 and x2 does not change any more. 
Thus, there are 2 steady state equations with 4 unknowns. Determining two of the unknowns will 
make it possible to solve the other two unknowns.  






Due to the simplicity of the system, one can easily see that b1 = v1 − v − 1 = b2. This suggests 
us if one of the b1, b2 or v1+v-1 is known, one can get the rest two. Then by knowing one of the 
v1 or v-1, one can know the other.  
By determining one of b1, b2 or v1+v-1, and one of v1 or v-1 the whole system can be solved.  
 
The equations above are linear algebra. A stoichiometric matrix S can be formed based on these 





= 𝑺 ∗ 𝑣(𝑥) = (
1 −1
0 1
   
 1 0
   −1 −1





)  =  (
𝑏1 − 𝑣1 + 𝑣 − 1
𝑣1 −  𝑣 − 1 −  𝑏2
)            
equation 13.3.3 
 
The S is called stoichiometric matrix. 





Figure 13.3 2 S matrix 
For this specific system (figure13.3.1), S is a 2-by-4 matrix (m*n matrix), meaning that it has 2 
metabolites and 4 unknown fluxes.  S with a rank r = 2, standing for the 2 linear independent 
equations can be written down because of 2 (m =2) metabolite chemical reactions (equation 13.3.1). 
There are 4 (n =4) columns in S indicating 4 unknown fluxes. In steady state, 
dx
dt
= S ∗ vss = 0. 
vss resides in the null space of S. Dimension of Dim(Null(S)) = n - r = 2 revealing that there are 
two free parameters for the steady state solutions of equation 14.3.1. The result of Null space of S: 
 








All steady state flux states of the system are a non-negative combination of these two vectors: 
 




It is not hard to find that this is another form of equation 13.3.2. One can substitute b1 = a, v1= a 
+ b, v-1= b, b2 =a, in equation 13.3.2 and get that  
 
𝑏1 − 𝑣1 +  𝑣 − 1 =   𝑎 − (𝑎 + 𝑏) + 𝑏 
= 0 
 
𝑣1 −  𝑣 − 1 −  𝑏2 =  (𝑎 + 𝑏) − 𝑎 − 𝑏 
= 0 
Proving that matrix offering the same solution as equation 13.3.2.  
Matrix is another form of setting up equations fundamentally, which helps us keep track of 






Figure 13.3 4 Comparison between equation form and matrix form 
 
 
The strength is not obvious in this simple system. However, one can explore more complex system 
and see how stoichiometric matrix help us understand the relation in glycolysis pathway 





Figure 13.3 5 Glycolysis  
Here’s the Mathematica simulation for solving steady state flux using matrix form 
(1) Define stoichiometric matrix. There are m=20 compounds and n=21 reactions.  S is a 







(2) Get the null space of S, the rank of S is r=18, so one can expect that the Null space is 3, 
Dim[Null(S)]] = n - r=21-18 = 3. 
 
(3) (Optional) Rearranging Null space so that the matrix looks neat. 
 
 
      
result from step1  
 
 








Take human red blood cell as an example. The uptake rate of the red blood cell of glucose is about 
1.12 mM/h (That will be 1.12*p1). The input of AMP is measured to be 0.014 mM/h. (That will 
be 0.014*p3).  The steady state load on NADH is 0.224 mM/h.(So 0.224*p2 ). 
vss= 1.12*p3+0.224*p2+ 0.014*p3 
 
 
In this model – for a bunch of complex pathways for each organ, matrix is going to give us useful 
information to help to solve the steady state.  
Above all the flux balance, the whole body has another layer of balance. The balance between 
different organs. For example, the total amount of glucose each organ uses to keep it functional 
should equate the total amount of glucose that liver produces. 
This should be true for all the macronutrient which can go into and out of the cell. (Including 
glucose, pyruvate, lactate, amino acid, glycerol, triglyceride). 
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Gathered are data for human overnight (typically 10 hours after dinner) macronutrient uptake and 
release rate. Adjust them within the physiology range to make sure one can get a balance between 
the organs that are about to be simulated. 
  
v GLC PYR LAC ALA FFA GLR TG 
Brain 0.38 0 0 0 0 0 0 
Heart 0.04 0 0.04 0 0.035 0 0 
Liver -0.731 0 0.27 0.32 0.21 0.14 -0.029 
GI_track 0.076 0 0 0 -0.12 -0.04 0.006 
Muscle 0.165 0.005 -0.112 -0.04 0.046 -0.003 0.003 
Adipose 0.038 0 -0.056 0 -0.211 -0.097 0.02 
Others 0.032 -0.005 -0.142 -0.28 0.04 0 0 
Sum 0 0 0 0 0 0 0 
Table 13.3 1 Macronutrient Uptake and release rates (mmol min-1) in each tissue/organ system 






13.4 Step 3: Express calculated flux with respect to metabolite concentration 
Enzymatic activity’s IRFE (Intracellular Reaction Flux Expression) involves several 
physiologically-based mathematical terms: In general, they are concentration of substrate (glucose 
etc.), phosphorylation state (ATP, ADP, AMP, ATP/ADP etc.), redox state (NAD, NADH, 
NAD/NADH etc.), product or third party allosteric stimulation and/or inhibition (AcCoA etc.). 
The IRFE assumes random sequential reaction. 
 
Hormonal actions (insulin/glucagon) can be expressed to directly affect enzymatic Vmax for each 
IRFE: Physiologically, insulin/glucagon do not go inside the cells but rather bind to ‘insulin 
receptor’ and ‘glucagon receptor’ which can stimulate/inhibit downstream signal processes. These 
signals (ie. PCK, FOXO etc., which were not considered at all in IRFE) affect IRFE; however, this 
problem can be temporarily circumvented if one assumes and expresses IRFE being 
stimulated/inhibited directly by hormonal actions. 
Two major parameters of interest are Km and Vmax for each IRFE.  
Km may be easier to get values than Vmax. They can be obtained from literature (most preferable 
and most widely used in research), optimized with multiple data points with manual adjustment 
(second most widely used), or assumed to be steady-state concentration of corresponding 
substrate/product.  
Hormones (insulin/glucagon/adrenaline etc.) and oxygen level (exercise etc.) can affect IRFE of 
glycolysis, TCA and other reactions via signaling. Blood flow rate can be also affected.  
Enzyme kinetics is the study of chemical reactions that are catalyzed by enzyme. As enzyme-
catalysed reactions are saturable, their rate of catalysis does not show a linear response to 
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increasing substrate (do not show the same pattern like first order reaction). Here several enzyme 
kinetics and their rate equations in term of substrate concentration are introduced. 
Competitive inhibition. 
Competitive inhibitors compete for the substrate-binding site of the enzyme with the substrate as 




Figure 13.4 1 Competitive inhibition 
 
 
There are  
E+S⇌ES⇌E+P 
E+I⇌EI 




𝑣 = 𝑣𝑚𝑎𝑥 ∗
[𝑆]








Some inhibitors bind only to the ES complex without binding to the free enzyme. This interaction 
scheme is illustrated in figure 13.4.2 
 
 
Figure 13.4 2 Uncompetitive inhibition 
There are  
E+S⇌ES⇌E+P 
ES+I⇌EIS 

















Noncompetitive inhibition  
In noncompetitive inhibition, the inhibitor binds to the enzyme at a location other than the active 
site in such a way that the inhibitor and substrate can simultaneously be attached to the enzyme.  
 
 
Figure 13.4 3 noncompetitive inhibition 



















Ping pong (bi-bi) mechanism  
Ping-pong mechanism, also called a double-displacement reaction, or bi-bi reaction is 
characterized by the change of the enzyme into an intermediate form when the first substrate to 
product reaction occurs. It is important to note the term intermediate indicating that this form is 
only temporary. At the end of the reaction the enzyme MUST be found in its original form. An 
enzyme is defined by the fact that it is involved in the reaction and is not consumed. Another key 
characteristic of the ping-pong mechanism is that one product is formed and released before the 





Figure 13.4 4 Bi-bi mechanism   
  
The Michaelis-Menten equation for this can be written as: 
 
𝑣 =
𝑣𝑚𝑎𝑥 ∗ [𝐴] ∗ [𝐵]
𝑘𝑖𝑎 ∗ 𝑘𝑏 + 𝑘𝑏 ∗ [𝐴] + 𝑘𝑎 ∗ [𝐵] + [𝐴] ∗ [𝐵]
 
The four enzyme kinetics above are the most frequently used ones in this research’s system. Other 
enzyme kinetic equations that include but limit to activation, reversible catalysis also are part of 
the equations.   
 
13.5 Step 5: parameter optimization 
For this research’s differential system, one can use time vs. concentration to fit the parameters. 
However, there are always more than ten parameters. Using one group of concentration vs time 
data may not be valid enough. Therefore, the research came up with using metabolite concentration 
range, which is the easiest type of parameter to obtain, to optimize the parameters. 
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= 𝑏 − 𝑣 





steady state bss, Css 





𝑉𝑚𝑎𝑥 =  𝑏𝑠𝑠 ∗





= 𝑏 − (𝑏𝑠𝑠 ∗














plot v = (1 + Km) ∗
C
Km+C
  with different Km value. Because of the steady state, Vmax depends 





Figure 13.5 1 Different Vmax and Km combinations 
 
Enlarging the part within the green box, and if one perturbs the steady state, a new steady state is 
obtained. New steady state flux range is 0.995 to 1.005. 
And if the concentration range is 0.98 to 1.03 as shown in the figure below, those Km falling out 






Intracellular Metabolite Concentration In Each Tissue 
Substrate\Tissues Brain Heart Muscle GI Liver Adipose 
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GLC 1.12 1 0.48 1 8 2.54 
PYR 0.15 0.2 0.048 0.2 0.37 0.37 
LAC 1.45 3.88 1.44 3.88 0.82 0.82 
ALA 0 0 1.3 0 0.23 0 
GLR 0 0.015 0.064 0.015 0.07 0.22 
FFA 0 0.021 0.53 0.021 0.57 0.57 
TG 0 3.12 14.8 450 2.93 990 
O2 0.027 0.96 0.49 0.49 0.027 0.027 
CO2 15.43 20 15.43 15.43 15.43 15.43 
G6P 0.16 0.17 0.24 0.17 0.2 0.2 
GLY 2 33 95 33 417 0 
GAP 0.15 0.01 0.08 0.01 0.11 0.11 
GRP 0 0.29 0.15 0.29 0.24 0.24 
ACoA 0.068 0.0012 0.0022 0.0012 0.035 0.035 
CoA 0.06 0.012 0.018 0.012 0.14 0.14 
NAD 0.064 0.4 0.45 0.4 0.45 0.45 
NADH 0.026 0.045 0.05 0.045 0.05 0.05 
ATP 2.45 3.4 6.15 3.4 2.74 2.74 
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ADP 0.54 0.02 0.02 0.02 1.22 1.22 
Pi 2.4 1.66 2.7 1.66 4.6 4.6 
PCR 4.6 8.3 20.1 8.3 0 0 
CR 5.6 3.5 10.45 3.5 0 0 
 

























Figure 13.6 1 Sensititivity analysis  
 
Sensitivity analysis is measurement of body’s exposure to a drug, nutrient or metabolite as a result 
of a parameter change, under different conditions (postprandial, fasting etc). The parameter change 
can be marginal or big. The degree of body’s exposure can be defined as Area Under the Curve 
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(AUC) which computes time integral between initial and end concentration or flux. Sensitivity 
analysis can be performed at a fixed time or be transient.  
In this research’s case, there are more than 100 parameters which have to be obtained through 
literature search, educated guess based on diffusion or convection, or computational optimization 
against clinical and experimental data. Out of these parameters, there may be some parameter 
changes that change AUC more severely than others. The sensitive parameters can be further 
optimized to better fit the simulated plots against real physiological data while less sensitive 
parameters can be either lumped and optimized or disregarded for further optimization.  
The chosen sensitive parameters then can be used for analysis to figure out which reaction is more 
responsible for the change of AUC in both healthy and T2D patients. In case of T2D patients, such 
information can be used to develop drug which target a reaction of a certain organs/tissues/cells. 
For example, if one figures out which reaction in gluconeogenesis is more responsible, one can 






14. MODEL RESULTS 
14.1 Brain 
 
Figure 14.1 1 Brain metabolic pathway 
 





Figure 14.1 3 Brain flux homeostatic steady state  
  
 




Figure 14.1 5 Brain fasting condition 4.4mM glucose 
 




Figure 14.1 7 Brain fasting condition 3.5mM glucose 
 




Figure 14.1 9 Brain fasting condition 3mM glucose 
 
Figure 14.1 10 Brain fasting condition 3mM glucose 
Figure 14.1.1 is schematics of brain metabolism. As stated in previous chapters, brain has two 
in/out fluxes for glucose and ketone bodies.  
Both figure 14.1.2 and figure 14.1.3 show what happen to intracellular concentration of 
metabolites and fluxes during homeostasis. Every concentration and flux stays the same at its 
steady state value. This is an expected behavior because the blood macronutrient concentration is 
kept constant by infusion. 
Both figure 14.1.4 and 14.1.5 show what happen to the brain’s metabolite concentrations and 
fluxes during the first day of fasting. During the first day of fasting, as shown in previous chapter, 
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the concentration of blood macronutrient changes. Glucose and ketone bodies respectively will be 
4.4mM and 58μM concentration. Then the change in intracellular fluxes and concentrations are 
observed. The most important information one can pull from the simulation are those related to 
glucose and ketone body reactions. Especially, the ratio of vpyrcoa and vkbcoa indicate flux 
contribution of pyruvate and ketone bodies to produce acetyl co-A. This ratio in different days of 
fasting are summarized in figure 14.1.10. The intracellular ketone body concentration also 
increases due to brain absorbing more ketone bodies via facilitated diffusion. 
Rest of the figures 14.1.6 to 14.1.9 show extended fasting days with changing blood macronutrient 
(glucose and ketone bodies) concentration.  
Finally, the figure 14.1.10 compares the ratio of pyruvate and ketone bodies contribution to 
produce acetyl co-A. The contribution of each flux ratio is studied because by doing so, one can 
see how the brain’s ATP generation changes from glucose driven (glycolysis and TCA) to ketone 
bodies driven TCA. As expected, the ratio goes down as fasting days are extended. It indicates that 
brain uses more ketone bodies as fasting days last for ATP generation. This shows that this 





Figure 14.2 1 Muscle metabolic pathway 
 




Figure 14.2 3 Steady state in homeostasis at 4.4mM 
 




Figure 14.2 5 Muscle metabolic profiles at 8mM 
 
Figure 14.2 6 Muscle metabolic profiles at 8mM with energy decoupling 
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Figure 14.2 7 Muscle metabolic profiles at 8mM with energy decoupling 
 




Figure 14.2 9 Muscle metabolic profiles at 3mM 
 
Figure 14.2 10 Muscle metabolic profiles at 3mM with energy decoupling 
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Figure 14.2 11 Muscle metabolic profiles at 3mM with energy decoupling 
 




Figure 14.2 13 Muscle metabolic profiles at 4.7% of TEE   
 




Figure 14.2 15 Muscle metabolic profiles at 4.7% of TEE with energy decoupling 
 




Figure 14.2 17 Muscle metabolic profiles at 11% of TEE   
 




Figure 14.2 19 Muscle metabolic profiles at 11% of TEE with energy decoupling 
 
Figure 14.2 20 Comparison of energy fuel source contribution between original and energy 




Figure 14.2 21 Muscle sensitivity analysis 
 
Figure 14.2.1 shows schematics of muscle. Unlike brain, there are more macronutrients going into 
and out of the organ. As mentioned in previous chapters, muscle can use different substrates under 
different conditions. The goal of this muscle simulation, therefore, is to see if this research is able 
to predict what happens to a human body in terms of concentration and flux as demonstrated in 
brain section.  
Both figure 14.2.2 and 14.2.3 show the intracellular concentrations and fluxes are at homeostatic 
steady state values.  
Figure 14.2.4 to 14.2.7 show what happen to intracellular metabolism during hyperglycemia while 
other macronutrient concentrations are kept constant. However, there is a difference between 
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figure 14.2.4, 14.2.5 (first group) and 14.2.6, 14.2.7 (second group). As mentioned in previous 
chapter, the energy expenditure is decoupled from energy input. Triacylglycerides (TAG) 
expenditure (vtagbreak) is assumed to be only dependent on energy demand which can be 
expressed in terms of basal metabolic rate (BMR) and other energy use being derived from exercise, 
thermogenesis etc. The first group and second group under hyperglycemic condition show 
somewhat different concentration and flux profiles over time (12 hours). The difference is not 
obvious in this condition but the difference becomes obvious under exercise condition in terms of 
contribution of each flux ratio as demonstrated in brain section. However, with detailed studies 
such as TAG or glycogen depletion rate over time, one can conclude that energy decoupled 
(modified) figures are more accurate. This energy decoupling also removes some of the inherent 
stiffness of ordinary differential equations (ODEs).  
Likewise, figure 14.2.8 to 14.2.11 show concentration dependent versus energy decoupled 
(modified) simulations under hypoglycemic condition. The decrease in TAG and glycogen 
concentration and rate changes are somewhat different as well.  
Figure 14.2.12 to 14.2.19 show concentration dependent versus energy decoupled profiles under 
two different exercise intensity regimes (4.7% of total energy expenditure and 11% of total energy 
expenditure). Both intensities are part of light exercises. The profiles are different not just when 
comparing unmodified versus modified profiles but also when exercise intensities change. The 
depletion in glycogen and TAG are steeper in as exercise gets more demanding. 
Figure 14.2.20 shows the ratio of contribution of two fluxes: vpyrcoa and vfacoa. It should be 
noted that muscle measures the ratio between pyruvate to acetyl co-A flux and fatty acid to acetyl 
co-A flux instead of ketone bodies to acetyl co-A flux. It is because the muscle will switch the 
macronutrient usage proportions between glucose or fatty acid under different exercise intensities. 
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The simulations show two strikingly different profiles of the ratios at different exercise intensities 
for unmodified and modified cases. What is expected physiologically is the increase in fatty acid 
contribution as exercise intensity increases within light intensity regime. The modified profile 
clearly shows that as exercise intensity increases from 4.7% to 9% to 11%, the fatty acid 
contribution to production of acetyl co-A increases. The unmodified case simulations, however, 
fail to show such trends. This shows that this research’s muscle mathematics are acceptable. 
Lastly, figure 14.2.21 shows sensitivity analysis. 20% change in parameters (vertical) lead to both 
positive and negative exposure of metabolites (area under the curve, AUC) to a human body 
(horizontal). The redder the color is, the exposure becomes positively larger while the bluer it is, 
the exposure becomes negatively larger. The sensitivity values are normalized so that the 
maximum absolute value of both positive and negative values should be 1.  
 
14.3 Adipose tissues 




Figure 14.3 2 Adipose tissues metabolic profiles at 3mM 
 




Figure 14.3 4 Adipose tissues metabolic profiles at 8mM 
 




Figure 14.3 6 Adipose tissues sensitivity analysis 
 
Figure 14.3.1 shows schematics of adipose tissues. The most important metabolite in adipose 




Figure 14.3.2 to 14.3.5 show adipose tissue metabolism under hyperglycemic and hypoglycemic 
conditions. Under former case, the storage of small of amount of glycogen and TAG lipid droplet 
increase. TAG concentration increases due to glucose contribution where glucose turns into G3P 
(vf6pg3p) and reacts with 3 FFA molecules to form a TAG molecule. Therefore, the physiological 
data that glucose is a precursor for G3P for TAG synthesis is demonstrated in hyperglycemic 
condition in this simulation. On the other hand, the latter case shows the glycogen and TAG lipid 
droplet decreasing in concentration. It is because the glycogen and TAG have to be mobilized to 
compensate for lower blood concentration. While it is BMR that drives TAG to break down 
(constant rate), the net TAG synthesis decreases due to lower blood concentration, hence lower 
TAG synthesis precursors (G3P), which leads to decrease in vtagsyn rate. Therefore, what this 
research’s simulations predict against the physiological data is acceptable and shows a good profile 
trend. 
Lastly, sensitivity analysis shows the exposure of metabolites to a human body due to 20% change 
in parameters. Just like muscle’s case, there are both positive and negative exposures as a result of 










15. INTERACTIVE APPLICATION 
 
Figure 15 1 Interactive application codes  
After previous steps are done, one may want to make an application where one can dynamically 
interact with the graphs, charts etc. With different data of the user’s choice fed as input, the output 
will be accordingly recalculated and show the updated graphs, charts, numbers etc. This can be 
realized by using any of the interactive functions of some programming languages of choice. In 
python there are bokeh or dash libraries, in Wolfram Mathematica, there is animate function and 
in R, there is shiny library.  
The given example is R shiny library’s example codes. The shiny app can be executed by writing 
two separate files: ui.R and server.R files, albeit now both ui and server can be incorporated into 
a single file. ui.R file allows the users to feed input data. Examples of input data could be numbers 
or item which the users can enter by sliders, radio buttons, dropdown bar etc. server.R file does all 
the computation of information which ui.R sent. The codes to generate graphs, bars, charts and so 
on are in server.R file. The difference between merely executing such codes and server.R is better 
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interactivity between users and the program, a.k.a. application. Making a shiny app once the full 




16. WHAT TO IMPROVE 
To further improve our model, we need to add and/or modify the following. 
First, we need to add additional hormonal effects such as adrenaline. Adrenaline will introduce 
extra glucose release effect during exercise. 
Second, blood flow rate change should be considered during exercise and hormonal exposure. 
This way, more precise physiological change can be represented. 
Third, exercise effects should be more clear. Exercise effect does not just release hormones but 
stimulate different nerves for different organs. Moreover, energy decoupling equation should 
include exercise terms in terms of work rate or % of VO2max. 
Fourth, oxygen levels should be added. According to Ashworth (2016), different oxygen level 
can bring about differentiated enzyme expressions within the same organ (periportal vs 
pericentral). The oxygen concentration effect may also be used to better explain TCA and 
exercise. 
Fifth, signaling molecules and transcription factors can be added to our ODEs to further make 
our model accurate. This way, we can better show molecular etiology and long term effects. 
Sixth, all the organs models have to be connected with arterial and venous blood flow. This is to 
achieve this research's goal of making a comprehensive physiological model. 
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➢ Achieved outstanding academic record (4.0/4.0) in Spring quarter at UC Davis  
‘Jilli’ Outstanding Academic Scholarship      
[NOV 2011] 
Yonsei University, Seoul, South Korea 
Relevant Activities 
Grader for Thermodynamics Course at Johns Hopkins University 
 [AUG 2017 ~ DEC 2017] 
Johns Hopkins University, Baltimore, MD, USA 
Bristol-Meyers Squibb Field Trip 
[OCT 2016] 
Bristol-Meyers Squibb Pharmaceuticals, Princeton Pike, NJ, USA 
National Chemical Engineering Qualification Certification (License, South Korea) 
[MAY 2015] 
➢ Passed National Chemical Engineering Qualification Exam and acquired certification 
and license during military service   
   WIPO (World Intellectual Property Organization by the United Nations)  
Trainee on Intellectual Properties 
[JUL 2013] 
Intellectual Property and Patent Training Center, Daejeon, South Korea 
➢ Took many courses and gave presentations to WIPO delegates and professors on 
Intellectual Properties and protection of them 
Miscellaneous Experiences               
Military Service 
[MAR 2014 ~ MAR 2016 (Honorable Discharge)] 
Ministry of Health and Education Child Care Center, Suwon, South Korea 
Bom Bit (Volunteer Teaching Organization)    
[MAR 2010 ~ FEB 2014] 
Keumjang Temple 
➢ Educated students from economically challenged families in Math and English 
➢ Counseled students on personal and educational matters 
➢ Conducted weekly meetings to assess students’ progress as a leader 
➢ Trained teachers on curriculum, methods and logistics for Bom Bit as a leader 
Many English Communication and Presentation Courses Taken        
[MAR 2010 ~ DEC 2013] 
Yonsei University, Seoul, South Korea 
Language Skills 
Korean Native Speaker 
  English Fluent: 
      C1(advance high-fluent) Level of Common European Framework (CEF) 
TOEFL 112/120 
New GRE 159/168/4.0 
  Others   Basic knowledge in German, French, Spanish 
  Traditional Chinese  Intermediate knowledge in Traditional Chinese (as used in   
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